  EORTC  
Avenue E. Mounierlaan 83/11  
Brussel 1200 Bruxelles  
België – Belgique  
Tel: +32 2 77 4 16 11  
e-mail: eortc@eortc.be  
www.eortc.org  
 
EORTC Soft Tissue and Bone Sarcoma Group  
EORTC Radiation Oncology Group  
 
A phase III randomi zed study of 
preoperative radiotherapy  plus surgery 
versus surgery alone for patients with 
Retroperitoneal sarcoma  (RPS)  
 
EORTC protocol 62092 -22092  
([STUDY_ID_REMOVED])  
STRASS  
 
Study Coordinator :  Sylvie Bonvalot  
Study Co-Coordinator:  Rick Haas  
 
Protocol  
version  Date of PRC  
approval/notification  Amendment reference  
N° Classification  
Outline  August 30, 2010  ---- ---- 
1.0 March 25, 2011  ---- ---- 
1.1 January 24, 2012  1 Administrative  
1.2 February 15, 2012  2 Administrative  
2.0 February 28, 2014  3 Scientific  
3.0 September 24, 2014  4 Scientific  
3.1 September 26, 2016  5 Administrative  
 

EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  2 / 106 September 26, 2016  Version 3.1  / September 26, 2016       ©Copyright EORTC 2016 
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  3 / 106 September 26, 2016  Contact addresses  
Steering Committee:  S. Bonvalot, Department of Surgery, Insti tut Curie, Paris,  France  
P. Dei Tos, Department of Anatomic Pathology, General Hospital 
of Treviso, Treviso, Italy  
A. Gronchi, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, 
Milan, Italy  
R. Haas, Department of Radiation Oncology, The Netherlands 
Cancer Institute, Amsterdam  
P. Hohenberger, Universitaetsmedizin Mannheim, Mannheim, 
Germany  
C. Le Péchoux, Insti tut Gustave Roussy , Villejuif, Fran ce 
S. Marréaud, EORTC Headquarters, Brussels, Belgium  
M. Ouali, EORTC Headquarters, Brussels, Belgium  
F. Pédeutour, Laboratoire de Génétique Tumorale, Hôpital de 
l'Archet, Nice University Hospital , Nice, France   
Writing Committee:  S. Bonvalot , Institut Curie, Paris,  France  
A. Gronchi, Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, 
Milan, Italy  
R. Haas, The Netherlands Cancer Institute -Antoni Van 
Leeuwenhoekziekenhuis , Amsterdam , The Netherlands  
P. Hohenberger, Universitaetsmedizin Mannheim, Mannhei m, 
Germany  
C. Le Péchoux, Institut Gustave Roussy, Villejuif, France  
N. Penel, Centre Oscar Lambret, Lille, France  
EORTC Headquarters team, Brussels, Belgium  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  4 / 106 September 26, 2016  Study Coordinator :  Sylvie Bonvalot  
Phone:  +33 1 56 24 57 69  
E-mail: sylvie.bonvalot@curie.fr  
Study Co -Coordinator:  Rick Haas  
Phone:  +31 20 5122124  
E-mail:  r.haas@nki.nl  
Clinical Research  
Physician:  Sandrine Marréaud  
Phone:  +32 2 774  16 85 
E-mail:   sandrine.marreaud@eortc.be  
Project  Manager s: Anne Kirkpatrick  
Phone:  +32 2 774  16 91 
E-mail:   anne.kirkpatrick@eortc.be  
 
Ward Sents  
Phone: + 32 2 774 1533  
E-mail:   ward.sents@eortc.be  
Data Manager:  Axelle Nzokirantevye  
Phone:  +32 2 774  16 62  
E-mail:   axelle.nzokirantevye@eortc.be  
Statistician:  Saskia Litiere  
Phone:  +32 2 774  10 73 
E-mail:   saskia.litiere@eortc.be  
Pharmacovigilance  Unit: Phone:  +32 2 774 16 76  
Fax: +32 2 772 80 27  
E-mail:   pharmacovigilance@eortc.be  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  5 / 106 September 26, 2016  Sponsor signatory page  
 
Protocol 62092 -22092  
 
Sponsor:  
 
__________________________________________ _________  __________________  
Vassilis Golfinopoulos       (Date)  
Medical Director   
EORTC  
European Organisation for Research and Treatment of Cancer  
AISBL -IVZW  
Avenue E. Mounierlaan  83/11  
Brussel 1200 Bru xelles  
België - Belgique  
Phone:  +32 (0)2 774 16 65 
E-mail:   vassilis.golfinopoulos@eortc.be  
Website: http://www.eortc.org  
 
 
Study Coordinator:  
 
___________________________________________________  __________________  
Sylvie Bonvalot        (Date)  
Institut Curie  
26, rue d'Ulm  
75248 Paris CEDEX 05  
France  
Phone :  +33 1 56  24 57 69  
E-mail:   sylvie.bonvalot@curie.fr   
 
Investigator: (if applicable)  
 
___________________________________________________  __________________  
Investigator’s name (printed clearly)      (Date)  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  6 / 106 September 26, 2016  Table of contents:  
Protocol summary  ................................ ................................ ................................ ................................ ........................  13 
1 Background  ................................ ................................ ................................ ................................ ..........................  18 
1.1 Retroperitoneal Sarcoma  ................................ ................................ ................................ ............................  18 
1.2 Outcome  ................................ ................................ ................................ ................................ .....................  18 
1.3 Current surgical issues  ................................ ................................ ................................ ................................  19 
1.4 Radiotherapy  ................................ ................................ ................................ ................................ ...............  20 
1.5 Rationale  ................................ ................................ ................................ ................................ .....................  23 
2 Objectives of the trial  ................................ ................................ ................................ ................................ ..........  23 
2.1 Primary objective  ................................ ................................ ................................ ................................ ........  23 
2.2 Secondary objectives  ................................ ................................ ................................ ................................ .. 23 
2.3 End-points  ................................ ................................ ................................ ................................ ...................  23 
2.3.1  Primary endpoint  ................................ ................................ ................................ ................................ .... 23 
2.3.2  Secondary endpoints  ................................ ................................ ................................ ..............................  23 
3 Patient selection criteria  ................................ ................................ ................................ ................................ ...... 24 
3.1 Tumor -related criteria  ................................ ................................ ................................ ................................  24 
3.2 Patient -related criteria  ................................ ................................ ................................ ................................  25 
4 Trial Design  ................................ ................................ ................................ ................................ ..........................  26 
5 Therapeutic regimens, expected toxicity, dose modifications  ................................ ................................ ............  28 
5.1 Standard arm: Surgery alone  ................................ ................................ ................................ ......................  28 
5.1.1  Operability criteria  ................................ ................................ ................................ ................................ .. 28 
5.1.2  Recommended surgical procedure  ................................ ................................ ................................ .........  28 
5.1.3  Recommendations for perioperative management  ................................ ................................ ...............  29 
5.1.4  Expected toxicity ................................ ................................ ................................ ................................ ..... 29 
5.2 Investigational arm - radiotherapy and surgery  ................................ ................................ ..........................  29 
5.2.1  Preoperative radiotherapy  ................................ ................................ ................................ .....................  29 
5.2.1.1  Interval between randomization and start of radiotherapy  ................................ ..........................  29 
5.2.1.2  Patient immobilization and data acquisition  ................................ ................................ .................  30 
5.2.1.2.1  Preparation for planning CT -simulation  ................................ ................................ ..................  30 
5.2.1.2.2  Bowel preparation  ................................ ................................ ................................ ...................  30 
5.2.1.2.3  Bladder preparation  ................................ ................................ ................................ .................  30 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  7 / 106 September 26, 2016  5.2.1.2.4  Oral and intravenous contrast agents  ................................ ................................ .....................  30 
5.2.1.2.5  Planning CT -simulation  ................................ ................................ ................................ ............  30 
5.2.1.2.6  Co-registration with other imaging modalities  ................................ ................................ ........  31 
5.2.1.3  Definition and delineation of target volumes  ................................ ................................ ................  31 
5.2.1.3.1  Gross Tumor Volume  ................................ ................................ ................................ ...............  31 
5.2.1.3.2  Clinical Target Volume  ................................ ................................ ................................ .............  31 
5.2.1.3.3  Planning Target Volume  ................................ ................................ ................................ ..........  31 
5.2.1.3.4  Organs at risk  ................................ ................................ ................................ ...........................  31 
5.2.1.3.5  Facility and Equipment  ................................ ................................ ................................ ............  32 
5.2.1.3.6  Dose Prescription  ................................ ................................ ................................ .....................  32 
5.2.1.3.7  Treatment Planning  ................................ ................................ ................................ .................  32 
5.2.1.3.7.1  General Guidelines  ................................ ................................ ................................ ...........  32 
5.2.1.3.7.2  Planning Priorities  ................................ ................................ ................................ ............  33 
5.2.1.3.7.3  Overall Treatment Time (OTT)  ................................ ................................ .........................  33 
5.2.1.3.7.4  Treatment Verification  ................................ ................................ ................................ ..... 33 
5.2.1.3.7.5  Treatment Modifications or Interruptions  ................................ ................................ .......  34 
5.2.2  Surgery after preoperative radiotherapy  ................................ ................................ ...............................  34 
5.2.2.1 Operability criteria  ................................ ................................ ................................ .........................  34 
5.2.2.2  Recommended surgical procedure  ................................ ................................ ................................  34 
5.2.2.3  Recommendations for perioperative management  ................................ ................................ ...... 35 
5.2.2.4  Expected toxicity  ................................ ................................ ................................ ............................  35 
5.3 Treatment modifications  ................................ ................................ ................................ ............................  35 
5.3.1  Surgery  ................................ ................................ ................................ ................................ ....................  35 
5.3.2  Radiotherapy  ................................ ................................ ................................ ................................ ..........  36 
5.3.3  Withdrawal criteria  ................................ ................................ ................................ ................................ . 36 
5.4 Concomitant treatment and supportive care management ................................ ................................ .......  36 
5.4.1  Permitted  ................................ ................................ ................................ ................................ ................  36 
5.4.2  Not permitted  ................................ ................................ ................................ ................................ .........  36 
6 Clinical evaluation, laboratory tests and follow -up ................................ ................................ .............................  37 
6.1 Clinical evaluation in both arms, bef ore randomization  ................................ ................................ ............  37 
6.1.1  The following exams should be done within 28 days before randomization ................................ .........  37 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  8 / 106 September 26, 2016  6.1.2  The following exams should be done within 21 days before randomization ................................ .........  38 
6.2 Surgery alone arm  ................................ ................................ ................................ ................................ .......  38 
6.2.1  Treatment period  ................................ ................................ ................................ ................................ ... 38 
6.2.1.1  The 15th day after the surgical procedure  ................................ ................................ ....................  38 
6.2.1.2  The 60th day after surgery  ................................ ................................ ................................ .............  39 
6.2.2  Follow up period  ................................ ................................ ................................ ................................ ..... 39 
6.2.2.1  Week 14 after randomization  ................................ ................................ ................................ ........  39 
6.2.2.2  24 weeks after randomization  ................................ ................................ ................................ .......  39 
6.2.2.3  36 weeks after randomization  ................................ ................................ ................................ .......  39 
6.2.2.4  48 weeks after randomization  ................................ ................................ ................................ .......  40 
6.2.2.5  After 48 weeks post randomization  ................................ ................................ ...............................  40 
6.3 Preoperative radiotherapy and surgery arm  ................................ ................................ ..............................  41 
6.3.1  During preoperative radiotherapy  ................................ ................................ ................................ .........  41 
6.3.1.1  Weekly  ................................ ................................ ................................ ................................ ...........  41 
6.3.1.2  Every 2 weeks  ................................ ................................ ................................ ................................  41 
6.3.2  2 weeks after the end of radiotherapy  ................................ ................................ ................................ ... 41 
6.3.3  Surgery  ................................ ................................ ................................ ................................ ....................  41 
6.3.3.1  Perioperative period  ................................ ................................ ................................ ......................  41 
6.3.3.2  The 15th day after the surgical procedure  ................................ ................................ ....................  42 
6.3.3.3  24 weeks after randomization  ................................ ................................ ................................ .......  43 
6.3.3.4  The 60th day after the surgical procedure  ................................ ................................ ....................  43 
6.3.4  Follow up period  ................................ ................................ ................................ ................................ ..... 43 
6.3.4.1  36 weeks after random ization  ................................ ................................ ................................ .......  43 
6.3.4.2  48 weeks after randomization  ................................ ................................ ................................ .......  44 
6.3.4.3  After 48 weeks post randomization  ................................ ................................ ...............................  44 
6.4 Summary tables  ................................ ................................ ................................ ................................ ..........  45 
6.4.1  Surgery alone arm  ................................ ................................ ................................ ................................ .. 45 
6.4.2  Radiotherapy followed by surgery arm  ................................ ................................ ................................ .. 47 
6.4.3 Collection of biological material for translational research  ................................ ................................ ... 50 
7 Criteria of evaluation  ................................ ................................ ................................ ................................ ...........  50 
7.1 Criteria for efficacy  ................................ ................................ ................................ ................................ ...... 50 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  9 / 106 September 26, 2016  7.1.1  Abdominal recurrence -free survival  ................................ ................................ ................................ .......  50 
7.1.2  Abdominal failure interval  ................................ ................................ ................................ ......................  50 
7.1.3  Metastases free survival  ................................ ................................ ................................ .........................  51 
7.1.4  Overall survival  ................................ ................................ ................................ ................................ .......  51 
7.1.5  Tumor response to preoperative radiotherapy  ................................ ................................ ......................  51 
7.1.5.1  Measurability of tumor lesions at baseline  ................................ ................................ ...................  51 
7.1.5.1.1  Definitions  ................................ ................................ ................................ ................................  51 
7.1.5.2  Methods of measurement  ................................ ................................ ................................ .............  53 
7.1.5.3  Tumor response evaluation  ................................ ................................ ................................ ...........  54 
7.1.5.4  Reporting of tumor re sponse  ................................ ................................ ................................ .........  56 
7.2 Evaluation of toxicity  ................................ ................................ ................................ ................................ .. 56 
7.2.1  Adverse events  ................................ ................................ ................................ ................................ .......  56 
7.2.2  Scales for toxicity evaluation  ................................ ................................ ................................ ..................  56 
7.2.2.1  Preoperative period  ................................ ................................ ................................ .......................  56 
7.2.2.2  Perioperative period (including per - and immediate postoperative periods)  ...............................  56 
7.2.2.3  Follow -up period  ................................ ................................ ................................ ............................  57 
7.2.2.4  Summary  ................................ ................................ ................................ ................................ ........  57 
7.2.3 Safety during the preoperative period  ................................ ................................ ................................ ... 57 
7.2.4  Safety during the perioperative period  ................................ ................................ ................................ .. 58 
7.2.4.1  "Surgical complications"  ................................ ................................ ................................ ................  58 
7.2.5  Late toxicity  ................................ ................................ ................................ ................................ ............  59 
7.2.6  Serious adverse events  ................................ ................................ ................................ ...........................  60 
7.2.7  Toxic deaths  ................................ ................................ ................................ ................................ ............  60 
7.2.8  Evaluability for safety  ................................ ................................ ................................ .............................  60 
8 Statistical considerations  ................................ ................................ ................................ ................................ ..... 60 
8.1 Statistical design  ................................ ................................ ................................ ................................ .........  60 
8.1.1  Sample size  ................................ ................................ ................................ ................................ .............  60 
8.1.2  Randomization and stratifications  ................................ ................................ ................................ ..........  61 
8.2 Interim analyses  ................................ ................................ ................................ ................................ ..........  61 
8.3 Statistical analysis plan  ................................ ................................ ................................ ...............................  62 
8.3.1  Primary and secondary endpoints  ................................ ................................ ................................ ..........  62 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  10 / 106 September 26, 2016  8.3.2  Analysis populations  ................................ ................................ ................................ ...............................  62 
8.3.3  Statistical methods  ................................ ................................ ................................ ................................ . 62 
8.3.3.1  Main analysis of the efficacy endpoints (primary and secondary)  ................................ ................  63 
8.3.3.2  Analysis for Safety endpoints  ................................ ................................ ................................ .........  63 
8.3.3.2.1  Acute toxicity profile of preoperative radiotherapy  ................................ ................................  63 
8.3.3.2.2  Perioperative complications  ................................ ................................ ................................ .... 63 
8.3.3.2.3  Late toxicity of preoperative radiotherapy (>60 days after the surgery)  ................................  65 
8.3.4  Pre-planned sensitivity or exploratory analyses  ................................ ................................ ....................  65 
8.3.5  Data recoding and display  ................................ ................................ ................................ ......................  65 
8.4 End of study  ................................ ................................ ................................ ................................ ................  66 
9 Data Monitoring  ................................ ................................ ................................ ................................ ..................  66 
10 Quality of life assessment  ................................ ................................ ................................ ................................ .... 66 
10.1  Rationale  ................................ ................................ ................................ ................................ .....................  66 
10.2  HRQoL instruments  ................................ ................................ ................................ ................................ ..... 67 
10.3  Study design  ................................ ................................ ................................ ................................ ................  68 
10.3.1  Timing of assessment  ................................ ................................ ................................ .........................  68 
10.3.2  HRQoL data collection  ................................ ................................ ................................ ........................  68 
10.3.3  Missing data  ................................ ................................ ................................ ................................ .......  68 
10.4  Statistical considerations  ................................ ................................ ................................ ............................  68 
10.4.1  Sample size  ................................ ................................ ................................ ................................ .........  68 
10.4.2  Primary HRQoL endpoint and hypothesis  ................................ ................................ ..........................  70 
10.4.3  Method for statistical analysis  ................................ ................................ ................................ ...........  70 
11 Translational research  ................................ ................................ ................................ ................................ .........  70 
11.1  Introduction  ................................ ................................ ................................ ................................ ................  70 
11.2  Informed consent  ................................ ................................ ................................ ................................ ........  71 
11.3  Human biological material  ................................ ................................ ................................ ..........................  71 
11.4  General principles for human biological material collection  ................................ ................................ ...... 71 
12 Investigator authorization procedure  ................................ ................................ ................................ .................  72 
13 Patient randomization procedure  ................................ ................................ ................................ .......................  73 
14 Forms and procedures for collecting data  ................................ ................................ ................................ ...........  75 
14.1  Case report forms and schedule for completion  ................................ ................................ ........................  75 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  11 / 106 September 26, 2016  14.2  Data flow  ................................ ................................ ................................ ................................ .....................  76 
15 Reporting of Serious Adverse Events ................................ ................................ ................................ ...................  76 
15.1  Definitions  ................................ ................................ ................................ ................................ ...................  76 
15.2  Exceptions  ................................ ................................ ................................ ................................ ...................  77 
15.3  Severity assessment  ................................ ................................ ................................ ................................ .... 77 
15.4  Causality assessment  ................................ ................................ ................................ ................................ .. 78 
15.5  Expectedness assessment  ................................ ................................ ................................ ...........................  78 
15.6  Reporting procedure for investigators  ................................ ................................ ................................ .......  78 
15.7  Reporting to investigators and competent authorities  ................................ ................................ ..............  79 
15.8  Pregnancy reporting  ................................ ................................ ................................ ................................ ... 79 
16 Quality assurance  ................................ ................................ ................................ ................................ ................  79 
16.1  Control of data consistency  ................................ ................................ ................................ ........................  79 
16.2  Audits  ................................ ................................ ................................ ................................ ..........................  80 
16.3  External review of histology ................................ ................................ ................................ ........................  80 
16.3.1  Forms  ................................ ................................ ................................ ................................ ..................  80 
16.3.2  Shipment of tumor samples  ................................ ................................ ................................ ...............  80 
16.3.3  Reference pathologist  ................................ ................................ ................................ ........................  81 
16.3.3.1  The list of reference pathologists  ................................ ................................ ..............................  82 
16.4  Other central review procedures  ................................ ................................ ................................ ................  82 
16.4.1  Quality assurance in radiotherapy  ................................ ................................ ................................ ..... 82 
16.4.1.1  Prior to authorization  ................................ ................................ ................................ ................  84 
16.4.1.1.1  Facility Questionnaire and External Reference Dosimetry Audit  ................................ ..........  84 
16.4.1.1.2  Dummy Run without delineation exercise (DR)  ................................ ................................ .... 84 
16.4.1.1.3  Complex Dosimetry Check  ................................ ................................ ................................ ..... 84 
16.4.1.1.4  Patient -specific RTQA program  ................................ ................................ .............................  84 
17 Ethical considerations  ................................ ................................ ................................ ................................ ..........  85 
17.1  Patient protection  ................................ ................................ ................................ ................................ .......  85 
17.2  Subject identification  ................................ ................................ ................................ ................................ .. 85 
17.3  Informed consent  ................................ ................................ ................................ ................................ ........  85 
18 Administrative responsibilities  ................................ ................................ ................................ ............................  86 
18.1  The study coordinator  ................................ ................................ ................................ ................................ . 86 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  12 / 106 September 26, 2016  18.2  The EORTC Headquarters  ................................ ................................ ................................ ............................  86 
18.3  The EORTC group  ................................ ................................ ................................ ................................ ........  88 
19 Trial sponsorship and financing  ................................ ................................ ................................ ...........................  88 
20 Trial insurance  ................................ ................................ ................................ ................................ .....................  88 
21 Publication policy  ................................ ................................ ................................ ................................ .................  89 
 
Table of appendices:  
Appendix A: References  ................................ ................................ ................................ ................................ ...............  90 
Appendix B: Abbreviations  ................................ ................................ ................................ ................................ ...........  93 
Appendix C: WHO performance status scale  ................................ ................................ ................................ ...............  96 
Appendix D: New York Heart Association (NYHA) classification of heart failure  ................................ .........................  97 
Appendix E: Calculation of the glomerular filtration rate (GFR)  ................................ ................................ ..................  98 
Appendix F: Common Terminology Criteria for Adverse Events  ................................ ................................ ..................  99 
Appendix G: EORTC Quality of Life e valuation: guidelines for administration of checklists  ................................ ...... 100 
Appendix H: American Society of Anesthesiologists score  ................................ ................................ ........................  102 
Appendix I: EORTC QlQ -C30 (version 3)  ................................ ................................ ................................ .....................  103 
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  13 / 106 September 26, 2016  Protocol summary  
Title of the Study  STRASS  - A phase III randomized study of preoperative radiotherapy plus surgery 
versus surgery alone for patients with Retroperitoneal sarcoma (RPS)   
Objective(s)  The main objective is t o assess whether preoperative radiotherapy , as an adjunct 
to curative -intent  surgery, improve s the prognosis of patients with RPS.  
Primary obj ective  
To assess whether there is a difference in abdominal recurrence -free survival 
between RPS patients undergoing curative -intent  surgery alone and those 
undergoing  preoperative radiotherapy followed by curative -intent surgery.  
Secondary objectives  
♦ To assess whether there is a difference in metastasis -free survival, abdominal 
recurrence free interval and overall survival between patients undergoing 
curative -intent surgery alone and those undergoing preoperative 
radiotherapy followed by curative intent s urgery  
♦ To assess tumor response in patients undergoing preoperative radiotherapy  
♦ To assess the toxicity profile of preoperative radiotherapy given as an 
"adjuvant" treatment to curative intent surgery in patients with RPS  
Methodology  Superiority phase III trial with stopping rules for the tolerance to protocol 
treatment  
Number of patients  The study is designed to provide 90% power to show an increase of 20% in the 5 -
year abdominal recurrence free survival rate (defined in chapter 7.1.1 ), from 50% 
to 70% (which corresponds to a hazard ratio of 0.52) at the 2 -sided 5% 
significance level: 256 patients will be randomized over 39 months . 
Diagnosis and main 
criteria for inclusion  A screening log form will be used in this protocol to collect information about 
failures of enrollment. (refer to section 6.1). 
Tumor -related criteria : 
♦ Primary soft tissue sarcoma of retroperito neal space or infra -peritoneal 
spaces of pelvis  
♦ Sarcoma not originated from bone structure, abdominal or gynecological 
viscera  
♦ Unifocal tumor (not multifocal disease)  
♦ Absence of exten sion through the sciatic notch or across the diaphragm  
♦ Histologically -proven RPS (local pathologist/ imaging -guided or surgical 
biopsy), excluding the following histological sub -types:  
♦ Gastro -intestinal stromal tumor (GIST)  
♦ Rhabdomyosarcomas  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  14 / 106 September 26, 2016  ♦ PNET or other small round blue cells sarcoma, osteosarcoma or 
chondrosarcoma  
♦ aggressive fibromatosis  
♦ sarcomatoid or metastatic carcinoma  
♦ Tumor not previously treated (no previous surgery -excluding diagnosis 
biopsy -, radiotherapy or syste mic therapy)  
♦ Tumor both operable and suitable for radiotherapy  
♦ This will be based on pretreatment CT scan /MRI and multidisciplinary 
consultation with surgeon, radiation oncologist and radiologist 
(anticipated macroscopically complete resection, R0/R1 resec tion)  
♦ Patients for whom surgery is expected to be R2 on the CT -scan before 
randomization are not eligible  
♦ Patients must have American Society of Anesthesiologist (ASA) score ≤ 2 
(see Appendix 8) 
♦ The criteria for non -resectability are:  
♦ (i) involvement of superior mesenteric artery  
♦ or (ii) involvement of aorta  
♦ or (iii) involvement of bone  
♦ No metastatic disease  
♦ Patien t must have radiologically  measurable disease (RECIST 1.1), as 
confirmed by abdomino -pelvic CT (IV and PO contrast) or MRI (with IV 
contrast) within the 28 days prior to randomization  
Patient -related criteria :  
♦ ≥ 18 years old  
♦ WHO  performance status ≤ 2 (see Appendix 3) 
♦ Absence of history of bowel obstruction or mesenteric ischemia or severe 
chronic inflammatory bowel disease  
♦ Normal renal function:  
♦ Calculated creatinin e clearance ≥ 50ml/min  (calculated by Cockcroft -
Gault; see Appendix 5) 
♦ Functional contra -lateral kidney to the side involved by the RPS as 
assessed by intravenous pyelogram (done dur ing the baseline CT -scan) or 
differential renal isotope scan  
♦ Normal bone marrow and hepatic function:  
♦ White Blood cells ≥ 2.5 x10 9 cells/L  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  15 / 106 September 26, 2016  ♦ Platelets ≥ 80 x10 9 cells/L  
♦ Total bilirubin < 2 time s the institutional upper limit of normal value 
(ULN)  
♦ Adequate  cardiac function: less or equal to NYHA II  
(see Appendix 4) 
♦ Normal 12 lead ECG (without clinically significant abnormalities)  
♦ Women of child bearing potential must have a negative pregnancy test within 
3 weeks prior to the first day of study treatment  
♦ Patients of childbearing / reproductive potential should use adequate birth 
control measures, as defined by the investigator, during the study treatment 
period and for at least 1 month after the surgery. A highly effective method 
of birth control is define d as those which result in low failure rate (i.e. less 
than 1% per year) when used consistently and correctly  
♦ Female subjects who are breast feeding should discontinue nursing prior to 
the first day of study treatment and for at least 1 month after the sur gery  
♦ No co -existing malignancy within the last 5 years except for adequately 
treated basal cell carcinoma of the skin or carcinoma in situ of the cervix  
♦ No relevant prior abdominal or pelvic irradiation precluding per protocol 
radiotherapy dose for other p rior malignancy or other disease  
♦ Absence of any psychological, familial, sociological or geographical condition 
potentially hampering compliance with the study protocol and follow -up 
schedule; those conditions should be discussed with the patient before 
randomization in the trial  
♦ Before patient randomization, written informed consent must be given 
according to ICH/GCP, and national/local regulations  
♦ Patients will be eligible for the translational research program if they are 
eligible for the clinical trial  and have given their written informed consent to 
participate in this program. If patient refuses to take part in the translational 
research project, patient remains eligible for the clinical trial  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  16 / 106 September 26, 2016  Treatment  
Test product, dose 
and mode of 
administration   
1) Preoperative  radiotherapy starting within the 8 weeks following the 
randomization: 28 daily fractions of 1.8 Gy (5 fractions per wee k) for a total dose 
of 50.4 Gy  
2) Re -assessment of operability  
3) Large en -bloc curative intent surgery within 4 -8 weeks following the end of 
radiotherapy   
Duration of treatment  
 Study t reatment will be given as indicated in the protocol unless any of the 
following events occur:  
♦ Disease progression  
♦ Occurrence of second malignancy  
♦ Unacceptable toxicity  based on the investigator's judgment  
♦ Patient  decision  
♦ After preoperative radiotherapy, patients for whom surgery is expected to be 
R2 on the CT -scan performed two weeks after the end of radiotherapy.  
Reference therapy, 
dose and mode of 
administration  Large en -bloc curative intent surgery within 4 weeks following randomi zation.  
Criteria for 
evaluation   
Efficacy  Abdominal recurrence free survival , abdominal failure interval, metastases free 
survival, overall survival, tumo r response to preoperative radiotherapy  
Safety  Two scales will be used for assessing adverse events:  
♦ CTCAE version 4.0: pre -operative period and follow up  
♦ Dindo  scale: perioperative period including per - and immediate 
postoperative periods (refer to chapter 7.2.2 ) 
Statistical methods  Two early safety chec ks will be p erformed after 33 and after 66 patients have 
been treated  in each arm with the aim of stopping the experimental arm if an 
absolute increase of 20% is observed in terms of reoperation rate or  if an 
absolute increase of  12% is observed in terms o f non -operable tumors as 
compared to the control group .  
The primary analysis and all efficacy endpoints  will be performed in the intention -
to-treat population.  
A 2-sided 5% significance level will be applied to all tests and confidence 
intervals.  
Abdomina l recurrence free survival (primary endpoint), metastatic free survival 
and overall survival will be described using Kaplan -Meier curves ( Ref. 29) in the 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  17 / 106 September 26, 2016  two treatment arms. The median survival time and its associated non -parametric 
confidence interval will be calculated.  
Abdominal failure interval will be described using cumulative incidence curves 
(Ref. 30).  
All efficacy endpoints will be compared between the randomized groups using 
the Cox’s proportional hazards model ( Ref. 31). For the competing risk endpoints 
(incidence of distant metastases) this will be a cause specific Cox's proportional 
hazards model.  
The analysis of the toxicity  endpoints will be performed in the safety population . 
The late toxicity will be inves tigated in the complete safety population.  
Translational 
research  All patients included in the clinical study will be offered to participate to the 
associated translational research project defined in section 10.1  and the 
prospec tive bio -banking of biological material at the time they are offered 
participation to the clinical study. The primary aim of the planned translational 
research is to establish new prognostic factors in patients with retroperitoneal 
sarcoma, especially lipo sarcoma.  
Quality of Life  The rationale for measuring HRQoL in this study is in measuring long -term impact 
related to surgical complication on patients’ well -being.  
Quality of Life will be measured by an ad -hoc checklist composed of validated 
QLQ questions  in order to measure fatigue, mobility, digestive troubles, sexual 
disorders and pain at baseline and years 1 and 5.  
PK – PD Not applicable  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  18 / 106 September 26, 2016  1 Background  
1.1 Retroperitoneal Sarcoma  
Approximately 10 -15% of adult soft tissue sarcomas arise in the retroperitoneum (Ref. 1). The mean annual 
incidence is 2.7 cases per 106 persons and does not change si gnificantly over time (Ref. 1). The sex ratio is 
approximately  1, and the median age at diagnosis is about 55 (Ref. 1, Ref. 2, Ref. 3, Ref. 4).  
The most frequent histological subtypes are:  
♦ well-differentiated liposarcomas  
♦ dedifferentiated liposarcomas  
♦ leiomyosarcomas (Ref. 2, Ref. 3, Ref. 4) 
Most of the previously so -called “malignant histiocyto -fibroma” or “malignant mesenchymoma” are now classified 
as dedifferentiated liposarcomas (Ref. 5). About two thirds of retroperitoneal soft tissue sarcomas are 
intermediate or high -grade tumors (Ref. 2, Ref. 3, Ref. 4).  
In this trial, we define as retroperitoneal sarcoma (RPS) all sarcoma arising in soft tissue of the retroperitoneum 
and the infra -peritoneal pelvic space; excluding sarcoma originating from viscera (intra -abdominal and 
gynecol ogical) ( Ref. 1, Ref. 2, Ref. 3, Ref. 4, Ref. 5). 
1.2 Outcome  
RPS are marked by a poor outcome, especially over  the long term . The 5 -year overall survival rate is 50 -60% , 
significantly worse than soft tissue arising from an extremity ( Ref. 2, Ref. 3, Ref. 4). The poor outcome of RPS is not 
explained by the occurrence of metastas es, as only about 13%  of patients experience distant metastas es at 5 years 
(Ref. 3). The major event leading the poor outcome is local recurrence. The local -recurrence -free survival at 5 y ears 
is 52 -60% (Ref. 2, Ref. 3, Ref. 4). This is explained by the following phenomena : 
♦ A large median tumor size at diagnosis of 15-18 cm ( Ref. 2, Ref. 3, Ref. 4) 
♦ This specific anatomic site implies proximity to and often i nvasion of contiguous vital structures and organs. 
This makes complete resection with negative margins difficult ( Ref. 2, Ref. 3, Ref. 4) 
♦ Up to  50% of patients are treated by non experienced surgical teams ( Ref. 2) 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  19 / 106 September 26, 2016  Table 1 - Summary of the 4 largest retrospective studies  
 Lewis et al. (Ref. 
4) Gronchi et al.  
(Ref. 3) Gronchi et al.  
(Ref. 3) Bonvalot et al.  
(Ref. 2) 
Period  1982 -97 1985 -2001  2002 -2007  1985 -2005  
Study  Single -center  Single -center  Single -center  Multicenter  
cases  278 136 152 382 
Median age (y.o)  58 (16 -88) 56 (46 -65) 55 (47-67) 57 (14 -87) 
Median size (cm)  - 15 (10 -28) 18 (10 -26) 18 (3 -60) 
Grade  
High  
Intermediate  
Low 
Not done   
64%  
- 
36%  
-  
33%  
29%  
38%  
-  
27%  
39%  
34%  
-  
32%  
34%  
29%  
5% 
Histology  
Liposarcoma  
Leiomyosarcoma  
Others   
41%  
27%  
32%   
56%  
15%  
29%   
59%  
13%  
28%   
44%  
18%  
38%  
5-y OS  ? % 51%  60%  57%  
5-y local 
recurrence free 
survival  59%  Not done  Not done  Not done  
5-y probability of 
local recurrence  Not done  48%  29%  Not done  
5- y abdominal 
recurrence free 
survival (*)  Not done  Not done  Not done   51%  
(*) including peritoneal sarcomatosis and local relapse  
1.3 Current surgical issues  
The predictive factors for local recurrence after primary treatment are currently unclear as most of studies merge 
primary and recurrent RPS (Table 2). The potential predictiv e factors for local recurrence are high grade ( Ref. 2, 
Ref. 4, Ref. 6), dedifferentiated liposarcoma ( Ref. 4), margins of resectability ( Ref. 2,  
Ref. 7), surgery performed in reference centers ( Ref. 2) and perioperative radiotherapy ( Ref. 2, Ref. 6). Tumor size 
is not a predictive factor for local relapse ( Ref. 2, Ref. 4). For decades, patients have been relatively under -treated 
with debulking surgery or partial resection. The retrospective studies of Bonvalot et al. and Gronchi et al. suggest 
that extensive surgery improves  outcome s (Ref. 2, Ref. 3). In the study of Bonvalot, “compartmental complete 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  20 / 106 September 26, 2016  resection” represents the systematic resection of uninvolved contiguous organs in order to obtain a rim of normal 
tissue surrounding the tumor (like muscles in limb sarcomas), thus ensuring wide margins. This type of surgery was 
performed since the 90’s by 3 high volume centers participating to the study. Typically, the patient underwent an 
en bloc tumor resection with the colon in front, the kidney inside and the psoas (or its apone urosis) at the back. 
Compartmental resection led to a 3.29 -fold decrease in the local recurrence rate with a 3 -year recurrence rate of 
10% compared to 50% with standard procedures. In the first study of Gronchi, from 1985 to 2002, the surgery was 
considered as non optimal in most cases; then the 5 -year local -recurrence free survival was 52%. From the 
beginning of 20 02, in a second study, Gronchi et al. have considered all patients for extensive surgery, which 
comprised liberal en -bloc resection of surrounding tissues and organs when they are located within 1 to 2 cm from 
the surface tumor, even when not infiltrated (Ref. 3). Therefore, the current surgical approaches implies the 
resection of one surrounding organ in 30% of cases and 2 or more surrounding organs in 50% of cases (Ref. 3). 
With this practice their 5 -year local -recurrence free survival went up to 71%.  
These 2 studies underline that the main factor that contributes to reduce the lo cal relapse rate is the surgeon's 
expertise.   
Nevertheless, despite extensive resections, the result of the surgical procedure cannot be coded according to the 
classical “R0, R1 and R2 classification”. The determination of “R0” status for RPS is problemati c because of the 
large tumor surface. Complete examination of the tumor specimen is often not feasible. Areas that appear grossly 
suspicious are typically selected for sampling, along with multiple random sections. Therefore, it is not often 
possible to cl aim R0 status. The presence of gross residual disease after resection has been reported as the most 
significant predictor of tumor -related death ( Ref. 2, Ref. 3, Ref. 4, Ref. 8, Ref. 9, Ref. 10).  
The perioperative mortality is about 3 -4% (Ref. 2, Ref. 4, Ref. 11). About, 10 -12% of patients undergo a re -
operation for complications  (Ref. 11). In the French and Italian retrospective study, the most frequent 
postoperative complications are anastomotic leakage (23/249), infected retroperitoneal collection (10/249), 
postoperative bleeding (6/249) and wound dehiscence (4/249). Most of these compl ications occur within the 60 
days following the surgical procedure  (Ref. 11). 
Table 2 - Potential predictive factors for local recurrence identified  by multivariate ana lysis  
 Stoeckle 2001  
(Ref. 6) Singer 2003  
(Ref. 10) Hassan 2004  
(Ref. 7) Bonvalot 2009  
(Ref. 2) Lewis 1998  
(Ref. 4) 
cases  165 177 97 382 500 
Histology  No - No No Yes (Lipo)  
Grade  Yes No - Yes Yes 
Margins  - - Yes Yes No 
Reference 
center  - - - Yes - 
Radiotherapy  Yes - - Yes - 
1.4 Radiotherapy  
Due to  the infiltrative nature of RPS, their proximity to vital organs and the difficulty to achieve an en-bloc 
resection, numerous investigators have addressed the role of pre- and postoperative radiotherapy (Ref. 12, Ref. 
13, Ref. 14, Ref. 15, Ref. 16). 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  21 / 106 September 26, 2016  Several retrospective studies have suggest ed that (neo -)adjuvant radiotherapy significantly reduce s the risk of local 
recurrence (Ref. 2, Ref. 3, Ref. 6, Ref. 17, Ref. 18, Ref. 19). In a large multicenter retrospective analysis, the 3 -year 
local recurrence rate was 49% without radiotherapy compared to 34% with radiotherapy (HR=0.64 , p<0.005 ) (Ref. 
2). Nevertheless, radiotherapy for RPS i s complex b ecause of the frequently large field sizes and the proximity of 
radiosensitive tissues  and organs.  
Intra operative radiotherapy (IORT) require s specific equipment, expertise and logistics  and therefore its use is 
restricted to specialist sarcoma centers on ly (Ref. 20).  
Preoperative radiotherapy is prefer red to postoperative radiotherapy for the following reasons  (Ref. 14): 
♦ The tumor is in situ making delineation and treatment planning more straightforward  
♦ The tumor may displace radiosensitive structures outside the treatment field  
♦ The biologically effective dose of radiation  required may be lower before surgery than after surgery due to less 
hypoxia  
♦ Higher doses can be delivered to tumor field because of fewer surgical adhesions  
♦ The t umor is treated in situ prior to potential contamination of the peritoneal cavity  
♦ Consequently, lower rates of acute and late toxicity may be seen and long term function may be better ( Ref. 
21)  
Jones et al. have reported their experience with preoperative external  beam radiotherapy ± postoperative 
brachytherapy  in 41 patients with  localized RPS (Ref. 15). The median preoperative dose was 45 Gy ( range 42-50 
Gy). No patients required hospitali zation  and none terminated radiotherapy because of acute toxicity, although 
one patient had to delay radiotherapy because of acute nausea and vomiting. Thirty percent  of patients 
experienced upper  gastro -intestinal tox icity grade 2 (RTOG acute toxicity score). Postoperative mortality was 2%. 
Fifty percent of operated patients received additional postoperative radiotherapy (median dose 25 Gy;  range  7.3-
30 Gy). 6 out 19 of patients experienced life-threatening toxicity du e to post operative radiotherapy. The 5 -year 
local -recurrence free rate was 60%. The rate of toxic death was 2/41 (5%) (Ref. 15). This stud y highlights the 
potential toxicity of additional postoperative radiotherapy  delivered after preoperative irradiation and surgery .  
After surgery and radiotherapy, patients are at risk of several l ate normal tissue complications such as  
(Ref. 12, Ref. 13):  
♦ small bowel compli cations (mal -absorption syndrome, adhesions, perforation, fistula)  
♦ neurotoxicity (radiation myelitis, sacral plexopathy)  
♦ kidney damage (reduced glomerular filtration, hypertension)  
♦ liver damage  
♦ secondary malignancies in the irradiated field  
In a Phase I t rial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and 
intraoperative electronbeam radiation therapy for patients with localized RPS, Pisters (Ref. 27Error! Reference 
source not found. ) included 35 patients with primary or recurrent intermediate - or high -grade RPS. Doxorubicin 
was administered each week for 4 or 5 weeks (initial b olus (4 mg/m2) followed by a 4 -day continuous infusion (4 
mg/m2/d). Preoperative radiotherapy  was administered in escalating doses: 18.0, 30.6, 36.0, 41.4, 46.8, or 50.4 Gy 
in 1.8 -Gy fractions. P atien ts with localized disease underwent surgical resection with IORT (15 Gy). At 50.4 Gy, 18% 
patients had grade 3 or 4 nausea. Grossly complete resection (R0 or R1) was performed in 90% patients who had 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  22 / 106 September 26, 2016  surgery and IORT was feasible and successfully administe red to 22 R0 or R1 patients. This study shows that 
preoperative chemo -radiation, surgical resection, and EB -IORT are feasible and that preoperative external  beam 
radiation can be administered to a total dose of 50.4 Gy with continuous  infusion  of doxorubic in.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  23 / 106 September 26, 2016  1.5 Rationale  
Radiotherapy seems to improve local control in retrospective studies but this potential advantage must be 
weighted in regards of potential side  effects. Preoperative  external beam radiotherapy  (EBRT ) is best tolerated 
and can be administer ed to a total dose of 50.4 Gy. Whereas in combined preoperative EBRT and IORT, much of 
the toxicity may be related to the IORT.  
This needs a formal phase III randomized study to evaluate the risk/benefit ratio of this approach with a control 
arm being sur gery alone and investigational arm being pre op radiotherapy.  
2 Objectives of the trial  
The main objective is t o assess whether preoperative radiotherapy , as an adjunct to curative -intent  surgery, 
improve s the prognosis of patients with RPS.  
2.1 Primary objectiv e 
To assess whether there is a difference in abdominal recurrence -free survival between RPS patients undergoing 
curative -intent  surgery alone and those undergoing  preoperative radiotherapy followed by curative -intent surgery.  
2.2 Secondary objectives  
♦ To asse ss whether there is a difference in metastasis -free survival, abdominal recurrence free interval and 
overall survival between patients undergoing curative -intent surgery alone and those undergoing preoperative 
radiotherapy followed by curative intent surgery  
♦ To assess tumor response in patients undergoing preoperative radiotherapy  
♦ To assess toxicity of preoperative radiotherapy given prior to curative intent surgery in patients with RPS  
2.3 End-points  
2.3.1  Primary endpoint  
The primary endpoint will be "abdomin al recurrence free survival" (see chapter 7). 
2.3.2  Secondary endpoints  
The safety secondary endpoints will be:  
♦ Acute toxicity profile of preoperative radiotherapy  
♦ Perioperative  complications  
♦ Late complications  
The efficacy secondary endpoints will be:  
♦ Tumor response to preoperative radiotherapy  
♦ Time to abdominal recu rrence  
♦ Metastasis -free survival  
♦ Overall surviv al 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  24 / 106 September 26, 2016  3 Patient selection criteria  
A screening log form will be used in this protocol to collect information about failures of enrollment. (refer to 
section 6.1). 
3.1 Tumor -related criteria  
♦ Primary soft tissue sarcoma of retroperito neal space or infra -peritoneal spaces of pelvis  
♦ Sarcoma not originated from bone structure, abdominal or gynecological viscera  
♦ Unifocal tumor (not multifocal disease)  
♦ Absence of extension through the sciatic notch or across the diaphragm  
♦ Histologically -proven RPS (local pathologist/ imaging -guided or surgical biopsy), excluding the following 
histological sub -types:  
♦ Gastro -intestinal stromal tumor (GIST)  
♦ Rhabdomyosarcomas  
♦ PNET  or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma,  
♦ Aggressive fibromatosis  
♦ Sarcomatoid or metastatic carcinoma  
♦ Tumor not previously treated (no previous surgery -excluding diagnosis biopsy -, radiotherapy or systemic 
therapy)  
♦ Tumor both operable and suitable for radiotherapy  
♦ This will be based on pretreatment CT scan /MRI and multidisciplinary consultation with surgeon, radiation 
oncologist and radiologist (anticipated macroscopically complete resection, R0/R1 resection)  
♦ Patients for whom surgery is expected to be R2 on the CT -scan before  randomization are not eligible  
♦ Patients must have American Society of Anesthesiologist (ASA) score ≤ 2 (see Appendix 8) 
♦ The criteria for non -resectability are:  
♦ (i) involvement of superior mesenteric artery  
♦ or (ii) involvement of aorta  
♦ or (iii) involvement of bone  
♦ No metastatic disease  
♦ Patien t must have radiologically measurable disease (RECIST 1.1), as confirmed by ab domino -pelvic CT (IV and 
PO contrast) or MRI (with IV contrast) within the 28 days prior to randomization  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  25 / 106 September 26, 2016  3.2 Patient -related criteria  
♦ ≥ 18 years old  
♦ WHO  performance status ≤ 2 (see Appendix 3) 
♦ Absence of history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease  
♦ Normal renal function:  
♦ Calculated creatinin e clearance ≥ 50ml/min  (calculated by Cockcroft -Gault; see  
Appendix 5) 
♦ Functional contra -lateral kidney to the side involved by the RPS as assessed by intravenous pyelogram 
(done during the baseline CT -scan) or differential renal isotope scan  
♦ Normal bone marrow and hepatic function:  
♦ White Blood cells ≥ 2.5 x10 9 cells/L  
♦ Platel ets ≥ 80 x10 9 cells/L  
♦ Total bilirubin < 2 time s the institutional upper limit of normal value (ULN)  
♦ Adequate cardiac function: less or equal to NYHA II (see Appendix 4) 
♦ Normal 12 lead ECG (without clinically significant abnormalities)  
♦ Women of child bearing potential must have a negative pregnancy test within 3 weeks prior to the first day of 
study treatment  
♦ Patients of childbearing / reproductive potential should use  adequate birth control measures, as defined by the 
investigator, during the study treatment period and for at least 1 month after the surgery. A highly effective 
method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when 
used consistently and correctly  
♦ Female subjects who are breast feeding should discontinue nursing prior to the first day of study treatment 
and for at least 1 month after the surgery  
♦ No co -existing malignancy within the last 5 years except for adequately treated basal cell carcinoma of the skin 
or carcinoma in situ of the cervix  
♦ No relevant prior abdominal or pelvic irradiation precluding per protocol radiotherapy dose for other prior 
malignancy or other disease  
♦ Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance 
with the study protocol and follow -up schedule; those conditions should be discussed with the patient before 
random ization in the trial  
♦ Before patient randomization, written informed consent must be given according to ICH/GCP, and 
national/local regulations  
♦ Patients will be eligible for the translational research program if they are eligible for the clinical trial and have 
given their written informed consent to participate in this program. If patient refuses to take part in the 
translational research project, patient remains eligible for the clinical trial  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  26 / 106 September 26, 2016  4 Trial Design  
This is an open -label randomized phase III superi ority trial  aiming to demonstrate that preoperative  radiotherapy 
(3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions ) increases the abdominal recurrence -free survival rate of 
patients with RPS treated with surgery compared to patients treated with surgery alone.  
The study is designed to provide 90% power to show an increase of 20% in the 5 -year abdominal recurrence fre e 
survival rate (defined in chapter 7.1.1 ), from 50% to 70% (which corresponds to a hazard ratio of 0.52) at the 2 -
sided 5% significance level: 256 patients will b e randomized over 39 months .  
In addition, t wo early safety checks will be performed in each treatment arm, after 33 and then after 66 patients 
have been treated with each regimen  (see chapter 8) with the aim of stopping any treatment arm that increases 
the rate of reoperation by 20% or increases the proportion of non -operable tumors by 12% compared to the 
control group.  
Patients will be stratified by institution an d performance status.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  27 / 106 September 26, 2016   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ARM 1  
 
           Curative intent surgery alone  ARM 2  
 
1) Preoperative radiotherapy  within 8 weeks  
2) Repeat thoraco -abdomino -pelvic CT -scan 2 
weeks after the end of radiotherapy  
3) Curative intent surgery within 4 -8 weeks  Patients with primary untreated soft tissue sarcoma of retroperitoneum or pelvis  
 
 
 
 
 
 
 WITHIN 28 DAYS BEFORE RANDOMIZATION  (see chapter 6) 
▪ Thoraco -abdomino -pelvic CT -scan / MRI  
▪ Diagnostic Biopsy  
▪ Multidisciplinary discussion on treatment strategy  
Stratification By  
institution, 
performance status  
 R 
(1/1)  
 
FOLLOW UP DISEASE EVALUATION  
 
Arm 1:  14, 24, 36, 48 weeks after randomization and Q6 mo thereafter until recurrence or death.  
Arm 2:  24, 36, 48 weeks after randomization and Q6 mo thereafter until recurrence or death.  
FOLLOW UP SURVIVAL  
 
Both arms: after recurrence Q6 mo . 
 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  28 / 106 September 26, 2016  5 Therapeutic regimens, expected toxicity, dose 
modifications  
5.1 Standard arm: Surgery alone  
5.1.1  Operability criteria  
Patients for whom surgery is expected to be R2 on the CT -scan before randomization are not eligible.  
Surgical procedures have to be done within the defined timelines. Please make sure that the operability criteria are 
met before surgery:  
♦ Patients must ha ve American Society of Anesthesiologist (ASA) score ≤ 2 (see Appendix 8) 
♦ The criteria for non -resectability are:  
♦ involvement of superior mesenteric artery  
♦ or involve ment of aorta  
♦ or involvement of bo ne 
5.1.2  Recommended surgical procedure  
Surgery will be performed in the investigator 's site, following these key  recommendations:  
♦ Surgery will be performed as soon as possible  (within 4 weeks following the randomization ) 
♦ Preoperative s urgical evaluation will be performed for all patients on cross sectional imaging (both CT scan and 
MRI are allowed) within 28 days before randomization  
♦ A generous midline laparotomy is preferred, in order to carry out an explor ation of the whole abdominal cavity  
♦ Macroscopically complete resection (R0/R1) of the tumor mass will be performed with en -bloc organ resection 
as necessary, based on preoperative assessment and intraoperative findings  
♦ Ideally, the following organs should be resected when in proximity to the tumor surface: kidney, colon, psoas 
muscle or its aponevrosis (recommended but not required, systematic resection should be indicated in the 
operative form)  
♦ The following organs or structures should be resected only if directly infiltrated: duodenum , head of pancreas, 
liver, stomach, major abdominal vessels and nerves, bone  
♦ Operative report must clearly indicate: whether surgery is macroscopically complete or not, whether per 
operative rupture was done or not, whether no t involved organs were systematically resected or not. The best 
would be to insert these informations  in English at the end of the report: R2 yes/no; Rupture Yes/ No, not 
involved organs resection yes/ no  
The n ame of the surgeon  and data about  the type of surgery, extent and morbidity of the surgical intervention will 
be collected on a "Surgery Form". 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  29 / 106 September 26, 2016  If the patient has consented, during the surgical procedure the surgeon has to appropriately collect:  
♦ Tumor tissue  
♦ Abdominal wall fat  
♦ Peripheral blood  
5.1.3  Reco mmendations for perioperative management  
We strongly recommend a minimum 24 -hour stay in an intensive care unit after the surgical procedure.  
5.1.4  Expected toxicity  
According to the most recently published literature (Ref. 11) immediate postoperative complications are  to be 
expected in about 18% of patients, including : 
♦ Anastomotic leakage  
♦ Infected postoperative collection  
♦ Postoperative bleeding  
♦ Wound dehiscence  
♦ Limb c ompartmental syndrome  
About 12% of patients will require re -intervention, ma inly for:  
♦ Postoperative bleeding  
♦ Retroperitoneal abscess  
♦ Wound dehiscence  
Most of these complications occur within the month following surgery . In consequence, patients should  be 
carefully followed until hospital discharge (daily examination during hospital stay) and/ or morbidity up to the 60th 
postoperative day (see chapter 7). 
All complications requiring re -operation/percutaneous radiological drainage have to be considered as an SAE.  
5.2 Investigational arm - radiotherapy and surgery  
5.2.1  Preoperative radiotherapy  
Preoperative radiotherapy will be delivered via a 3D -CRT or IMRT technique  conducted according to EORTC RTQA  
guidelines.  
The preoperative radiotherapy should be performed in the same center as surgery. "Satelli te" centers are not 
allowed in this trial.  
5.2.1.1  Interval between randomization and start of radiotherapy  
Radiotherapy should be started within 8 weeks after randomization and will last for about 6 to7 weeks.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  30 / 106 September 26, 2016  5.2.1.2  Patient immobilization and data acquisition  
All p atients will be irradiated in the supine position, preferably with knee and ankle rests for support of the legs. 
The arms s hould be  out of the way of the beams; it is highly recommended that they are  rested in arm supports 
above the head. No specific immobilization device is mandatory, but one may be used  
(e.g. vacuum  fix bag).  
5.2.1.2.1  Preparation for planning CT -simulation  
All patie nts must undergo a planning CT -simulation for treatment planning.  
5.2.1.2.2  Bowel preparation  
No specific bowel preparation is required. However if the sarcoma is p rimarily located within the pelvis , the degree 
of rectal filling  should be assessed . If the patient has a significant amount of  air in the rectum (defined as ≥ 5cm 
rectal wall distention in the  transverse plane) , the patient should receive laxatives and be rescanned at least 2 days 
later.  
The bowel preparation adopted for the planning CT -simulation scan sh ould be maintained throughout each 
radiotherapy treatment.  
5.2.1.2.3  Bladder preparation  
No specific bladder pre paration is required. M ost patients are more comfortable with empty bladders. In the case 
of sarcomas above the promo ntorium the cranial disp lacement of the small intestine by a full bladder may  even be 
disadvantageous.  However, the preferred degree of bladder filling will be left to the discretion of the investigator 
as this may depend on the exact location and extent of the sarcoma.  
The bladder preparati on adopted for the CT -simulation scan should be maintained throughout each radiotherapy 
treatment.  
5.2.1.2.4  Oral and intravenous contrast agents  
To enhance vascular and soft tissue contrast and to facilitate delineation of both target volumes and organs at risk, 
the use of oral and intravenous contrast agents is  highly encouraged. Proto cols from the local radiology  
department can be used for this purpose.  
5.2.1.2.5  Planning CT -simulation  
The planning CT -simulation  scan should fulfill the following criteria:  
♦ Maximum slic e thi ckness 5 mm, preferably less (3mm)  
♦ Cranial slic e at or above the level of the tracheal bifurcation  
♦ Caudal slic e at or below the level of the lesser trochanter of the femur  
♦ Images will be reconstructed with at least 512 x 512 pixel matrices  
Respiratory gat ing or 4D reconstructions are not mandatory for this trial.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  31 / 106 September 26, 2016  5.2.1.2.6  Co-registration with other imaging modalities  
Co-registration with  the pre -radiotherapy  MRI is highly encouraged but not mandatory for this trial. If a baseline 
MRI is not available, co -registration can be performed with the pre -radiotherapy contrast -enhanced diagnostic CT. 
Local matching procedures are to  be used for this purpose.  
Co-regis tration with FDG -PET is discouraged because of lack of validation in the setting of sarcoma s. 
5.2.1.3  Definition and delineation of target volumes  
The definition of volumes will be in accordance with ICRU Reports 50, 62 and 83 ( Ref. 22, Ref. 23,  
Ref. 24). Volumes shall be delineated on each planning CT axial slice.  
5.2.1.3.1  Gross Tumor Volume  
The GTV will include the gross disease as visualized on the planning CT, any co-registration and any applicable 
diagnostic images.  
5.2.1.3.2  Clinical Target Volume  
The CTV will inc lude the GTV with a geographic expansion of 5 mm will be used, when the CT slice thickness is 5 
mm. It will be 6 mm when the slice thickness is 3 mm. This expansion takes in to account subclinical extension.  
Note that after three -dimensional generation of m argins, an anatomically reasonable correction should be 
performed at anatomic borders as necessary i .e. in directions where there is fasciae, bone, skin, or air gaps which 
are not at risk for microscopic disease. In general, the entire anatomic compartment need not be covered. In the 
rare case of the presence of suspicious edema, include this in the CTV. If  the suspicious edema extends outside of 
the 6  mm margin, expand the CTV to include the edema but do not add additional margin to this. We recommend 
the vertebral body to be excluded from the CTV. The biopsy tract does not need to be included to skin surfa ce. 
5.2.1.3.3  Planning Target Volume  
A safety margin will be implemented around the CTV to take into account patient set -up uncertainties and organ 
motion. PTV will include CTV plus an additional geometrical margin of 9 mm (anteriorly and medially) and 12 mm 
(superi orly, inferiorly, posteriorly and laterally). In the situation where the PTV is located within 5  mm of the 
body/external contour, a "PTV_internal" should be defined, which is the PTV collapsed inside the body/external 
contour by 5 mm . This is the structure  to be used for dosimetric evaluation.  
5.2.1.3.4  Organs at risk  
These are the normal tissue structures whose radiation sensitivity may significantly influence the treatment 
planning. Every effort should be made to avoid treating genitalia/perineum, lung, femoral hea ds and delivering full 
skin dose to areas commonly traumatized.  
Every effort should be made to avoid dose maxima in areas where surgical incisions will be placed. This may 
require reviewing treatment plans with the surgeon.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  32 / 106 September 26, 2016  Mandatory organs at risk (OAR)  to be delineated are:  
♦ The spinal cord: osseous borders of the vertebral canal  
♦ Both kidneys  
♦ Liver  
♦ Peritoneal cavity  (includes large and small bowel , but should not include stomach and duodenum ) 
♦ As the bowel is mobile, its location cannot be known on a dail y basis with high precision. An efficient, robust, 
and safe solution to this problem is to define the whole volume where the bowel loops can move inside the 
peritoneal cavity. This will be contoured as described in Sanguineti et al  (Ref. 25). It will be contoured 
superiorly to the level of the stomach/duodenum, anteriorly to the abdominopelvic wall, posteriorly to the 
pancreas/IVC/aorta/psoas muscles, laterally to the pelvic wall and inferiorly to the rectum/bladder .Peritoneal 
Cavity -PTV (which corresponds to peritoneal cavity outside the PTV)  
5.2.1.3.5  Facility and Equipment  
Institutions must comply with the RTQA  requirements and procedures described in the Quality Assurance in 
Radiotherapy chapter and in the " RTQA  Guidelines” which will be sent with the initiation package.  
Linear accelerators capable of delivering megavoltage photon beams are required (3D -CRT, IMRT [including 
tomotherapy]).  
For 3D -CRT, energies ≥ 6 MV are allow ed. 
For IMRT (including tomotherapy), only photon energies of 6 MV to 10 MV are allowed.   
Cobalt units, electrons and particle therapy are not allowed.  
5.2.1.3.6  Dose Prescription  
The prescribed dose will be 50.4 Gy  in 28 daily fractions, with five fractions of 1.8 Gy delivered per week over 5 1/2 
weeks.  
5.2.1.3.7  Treatment Planning  
The prescription dose is specified and reported at the ICRU reference point as defined in ICRU Reports 50, 62 and 
83 (Ref. 22, Ref. 23, Ref. 24). 
5.2.1.3.7.1  General Guidelines  
All patients will be treated with an isocentric technique. Volume -based field arrangements determined by 
conformal planning are left to the discretion of the investigators. Non -coplanar field arrangements are allowed. Al l 
fields will be treated every day.  
3D-CRT, IMRT (including tomotherapy) are allowed, with the selection of the technique left to the discretion of 
each center . The technique to be utilized for all patients entered in the trial must be declared prior to si te 
authorization. If a site wishes to upgrade from 3D -CRT to IMRT (including tomotherapy) during the study, all IMRT 
RTQA procedures should be completed first.  
It is highly recommended that treatment plans are computed using modern dose calculation algorit hms, such as 
convolution/superposition, Monte Carlo, collapsed cone or equivalent algorithms. Pencil beam algorithms should 
not be used for energies above 10 MV. All field entrance and exits should be covered by the CT -simulation scan 
volume, in order to a void inadequate dose calculations. The dose matrix to be used must be below 4 mm.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  33 / 106 September 26, 2016  The use of bolus is left to the discretion of the investigator.  
5.2.1.3.7.2  Planning Priorities  
Missing tissue compensation should be used if required to ensure sufficient dose homogenei ty.  
The planning priority will be : dose limitation s to OAR  followed by dose delivery to PTV .  
The following PTV dose constraints will be applied to optimize safety and minimize toxicity:  
♦ At least 95% of the PTV should receive  95% of the prescribed dose  
♦ No more than 10% of the PTV should receive more than 107% of the prescription dose  
♦ Coverage of the PTV by the 90% isodose (45.4 Gy) will be allowed in the case of close proximity to OARs  
Mandatory dose limitations to the follo wing OAR will be incorporated:  
♦ Contralateral kidney: < 2/3 of the kidney volume should receive ≥ 18 Gy  
♦ Spinal cord: ≥ 45 Gy over a maximum length of 2 cm and D2 < 50 Gy  
♦ Peritoneal Cavity -PTV (Peritoneal cavity outside the PTV ): < 195 cc to receive ≥ 45 Gy ( Ref. 39) 
♦ Liver: mean dose ≤ 26 Gy   
5.2.1.3.7.3  Overall Treatment Time (OTT)  
The specified dose (50.4 Gy/28 daily fractions) can be delivered in an OTT of 38 days. Equipment mainte nance and 
public holidays can be unavoidable reasons for treatment delays. Therefore:  
♦ an OTT up to and including 42 days will be regarded as adequate  
♦ an OTT up to and including 45 days will be regarded as minor protocol violation and reasons for the delay  must 
be specified  
♦ an OTT > 45 days will be regarded as a major violation and reasons for delay must be specified  
In case of treatment interruptions, missing fractions should be added at the end of the course.  
5.2.1.3.7.4  Treatment Verification  
Daily patient set-up shall be performed using laser alignment to reference marks on the skin of the patient. As a 
minimum requirement, an off -line set -up correction protocol must be in place that requires imaging at least once 
per week. It is highly advised to adhere to  the adapted "shrinking action level (SAL)" or extended "no action level 
(eNAL)" off -line protocols as described in the literature. Daily on -line set -up verification and correction is also 
allowed but not mandatory. A non -daily on -line correction protocol is not allowed. All protocols used shall be 
based on bony anatomy.  
If the total dose used for imaging is expected to exceed 2% of the prescribed dose, this should be taken into 
account during the treatment planning.  
Port films or electronic portal images will be obtained for all fields on the first day of treatment. It is recommended 
that this procedure be repeated on a weekly basis during treatment. Port films will be compared to localization 
films and/or digitally reconstructed radiographs and all discre pancies must be corrected. Alternatively, set -up 
corrections may be done according to local validated correction protocols.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  34 / 106 September 26, 2016  5.2.1.3.7.5  Treatment Modifications or Interruptions  
No modifications will be permitted with respect to the treatment volumes, dose prescription , allowable OAR doses 
or maximum OTT.  
5.2.2  Surgery after preoperative radiotherapy  
5.2.2.1  Operability criteria  
Patients for whom surgery is expected to be R2 on the CT -scan performed two weeks after the end of radiotherapy 
are not eligible for surgery.  
Patients will undergo surgery with an interval of 4 to 8 weeks between the end of radiotherapy and the surgery.  
Surgical procedures have to be done within the defined timelines. Patients operated later than 8 weeks after the 
end of radiotherapy will be considered as a f ailure. Please make sure that the operability criteria are met before 
surgery:  
♦ Patients must have American Society of Anesthesiologist (ASA) score ≤ 2 (see Appendix 8) 
♦ The criteria for non -resectability are:  
♦ involvement of superior mesenteric artery  
♦ or involvement of aorta  
♦ or involvement of bone  
5.2.2.2  Recommended surgical procedure  
Surgery will be performed in the investigator 's site, following the same key  recommendations  as in the standard 
arm:  
♦ Surgery will be performed: after a new thoraco -abdomino -pelvic CT -scan (12 weeks after the randomization) 
and within 4 -8 weeks after the completion of radiotherapy.  
♦ Note: patients that will not undergo their surgical procedure wi thin 8 weeks after the ending of the 
radiotherapy because of acute radiotherapy toxicity(ies) will be considered as " non operable tumors" (see 
chapter 8.2; interi m analysis - second interim analysis -) 
♦ Surgical evaluation will be performed for all patients, on cross sectional imaging (at baseline and after 
radiotherapy)  
♦ A generous midline laparotomy will be preferred, in order to carry out an exploration of the who le abdominal 
cavity  
♦ Macroscopically complete resection (R0/R1) of the tumor mass will be performed with en -bloc organ resection 
as necessary, based on preoperative assessment and intraoperative findings  
♦ The following organs should be resected when in proximity to the tumor surface: kidney, colon, psoas muscle 
or its aponevrosis (recommended but not required, systematic resection should be indicated in the operative 
form)  
♦ The following  organs or structures should be resected only if directly infiltrated: duodenum, head of pancreas, 
liver, stomach, major abdominal vessels and nerves, bone  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  35 / 106 September 26, 2016  ♦ Operative report must clearly indicate: whether surgery is macroscopically complete or not, whether  per 
operative rupture was done or not, whether not involved organs were systematically resected or not. The best 
would be to insert this information in English at the end of the report: R2 yes/no; Rupture Yes/ No, not 
involved organs resection yes/ no  
The name of the surgeon  and data about  extent and morbidity of the surgical intervention will be collected on a 
"Surgery Form". 
If the patient had consented, during the surgical procedure the surgeon has to appropriately collect:  
♦ Tumor tissue  
♦ Abdominal wall f at 
♦ Peripheral blood  
5.2.2.3  Recommendations for perioperative  management  
We strongly recommend a minimum 24 -hour stay in an intensive care unit after the surgical procedure.  
5.2.2.4  Expected toxicity  
According to the most recently published literature  (Ref. 11), immediate postoperative complications are  to be 
expected in about 18% of patients, including : 
♦ Anastomotic leakage  
♦ Infected postoperative collection  
♦ Postoperative bleeding  
♦ Wound dehiscence  
♦ Limb compartmental syndrome  
About 12% of patients will require re -intervention, ma inly for:  
♦ Postoperative  bleeding  
♦ Retroperitoneal abscess  
♦ Wound dehiscence  
Most of these complications occur within the month following surgery  (Ref. 11). In consequence, patients should  
be carefully followed until hospital discharge (daily examination during hospital stay) and/or every week beyond 
hospital discharge  up to the 60th postoperative  day (see chapter 7). 
All complications requiring re -operation/percutaneous radiological drainage have to be considered as an SAE.  
5.3 Treatment modifications  
5.3.1  Surgery  
Surgery arm alone: refer to section 5.1.1 . 
Radiotherapy and surgery arm: refer to section 5.2.2 . 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  36 / 106 September 26, 2016  5.3.2  Radiotherapy  
Preoperative radiotherapy has to be done within the defined timelines. Please respect the dose adaptation and 
duration of treatment described in chapters 5.2.1.3.7  and 5.2.1.3.7.3 . 
5.3.3  Withdrawal criteria  
Study t reatment will be given as indicated in the protocol unless any of the following events occur:  
♦ Disease progression  
♦ Occur rence of second malignancy  
♦ Unacceptable toxicity  based on the investigator's judgment  
♦ Patient  decision  
♦ After preoperative radiotherapy, patients for whom surgery is expected to be R2 on the CT -scan performed 
two weeks after the end of radiotherapy  
5.4 Concomit ant treatment and supportive care management  
Supportive care is left to investigator’s discretion.  
5.4.1  Permitted  
♦ Anticoagulants: warfarin, low molecular weight heparin or aspirin are allowed  
♦ Other concomitant medications: Anti -inflammatory or narcotic analge sics may be offered as needed. Packed 
red blood cell and platelet transfusions should be administered as clinically indicated  
♦ Patients on this trial may be supported with appropriate hormone replacement therapy in the event that the y 
develop adrenal insuff iciency  
♦ All appropriate supportive care (including enteral nutrition)  
5.4.2  Not permitted  
♦ Postoperative Radiotherapy  
♦ In case of R2 surgery, postoperative radiotherapy is allowed but the patient will be considered as a failure  
♦ In case of R1 surgery, postoperative  radiotherapy is not authorized since it is not a standard: benefit of 
adjuvant radiotherapy is the objective of this trial  
♦ All systemic anticancer treatment (chemotherapy, molecular targeted therapy …)  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  37 / 106 September 26, 2016  6 Clinical evaluation, laboratory tests and follow -up 
 
6.1 Clinical evaluation in both arms, before randomization  
A screening log form will be used in this protocol to collect information about failures of enrollment. On this form 
we will collect:  
♦ Age of the patient (not the date of birth)  
♦ Gender (male or female)  
♦ Reasons for not enrolling the patient like: patient’s refusal, screening failure … 
These data will be used in fully anonymized way . 
6.1.1  The following exams should be done within 28 days before 
randomization  
♦ Thoraco -abdomino -pelvic CT sca n with contrast injection, and in some cases with additional abdomino -pelvic 
MRI (with IV contrast) within the 28 days prior to randomization  
  

EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  38 / 106 September 26, 2016  6.1.2  The following exams should be done within 21 days before 
randomization  
♦ Medical history including associated chro nic diseases  
♦ Complete physical exam (performance status)  
♦ Assessment of ASA Score (by anesthesiologist)  
♦ Cancer signs and symptoms  
♦ Assessment of  adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemist ry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Renal function:  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Functional contra -lateral kidney to the side involved by the RPS as assessed by intravenous pyelogram 
(done during the baseline CT -scan) or differential renal isotope scan  
♦ 12 lead -ECG  
♦ Serum or urine pregnancy test (for women of childbearing potential)  
♦ Multidisciplinary documented discussion (involving at least the surgeon and the radiation oncologist) to 
confirm that tumor is both potentially resectable (anticipated R0/R1 resection) and suitable for radiotherapy  
♦ Imaging -guided or  surgical biopsy to confirm the histological diagnosis may have to be performed  
♦ Translational research: if patient consents, one blood sample of 5 mL to be collected (refer to chapter 11) 
♦ HRQoL checklist (refer to quality of life chapter  10) 
6.2 Surgery alone  arm 
Assessment of adverse events (refer sections 7.2.4 ). 
For the perioperative period (including per - and immediate postoperative periods), the scale used for assessing  the 
severity will be the Dindo scale ( Ref. 27). 
Translational research: if patient consents, one blood sample of 5 mL to be collected at the time of surgery.  
6.2.1  Treatment period  
6.2.1.1  The 15th day after the surgical procedure  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum che mistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  39 / 106 September 26, 2016  ♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
6.2.1.2  The 60th day after surgery  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine , AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
6.2.2  Follow up period  
The follow up period  starts after the day 60 th post surgery.  
Assessment of adverse events (refer section 7.2.5 ). 
For follow up period, the scale used for assessing the severity will be  CTCAE V.4.0.  
6.2.2.1  Week 14 after randomization  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomin o-pelvic CT scan with contrast injection, and in some cases MRI (with IV contrast)  
6.2.2.2  24 weeks after randomization  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood c ells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast, and on indication (when CT scan is doubtful) MRI (with IV 
contrast)  
6.2.2.3  36 weeks after randomization  
♦ Complete physical exam (performance status)  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  40 / 106 September 26, 2016  ♦ Cancer signs and  symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculate d by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast, and on indication (when CT scan is doubtful) MRI (with IV 
contrast)  
6.2.2.4  48 week s after randomization  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast, and on indication (when CT scan is doubtful) MRI (with IV 
contrast)  
6.2.2.5  After 48  weeks  post randomization   
Every 6 months until recurrence or death  
The following examinations and tests will be performed:  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Thoraco -abdomino -pelvic CT scan with contrast product injections, and on indication (when CT scan is 
doubtful) MRI (with IV contrast)  
Every 12 months until recurrence or death  
The following examinations and tests will be performed:  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin,  creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
At 1 year and 5 years pos t randomization  
♦ To complete the HRQoL checklist (refer to quality of life chapter 10) 
After recurrence  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  41 / 106 September 26, 2016  ♦ After recurrence, the patient should be followed every 6 months for survival and further antitumor therapy.  
6.3 Preoperative radiotherapy and surgery arm  
6.3.1  During preoperative radiotherapy  
Assessment of all adverse events (refer section  7.2.3 ). 
For the preoperative period the scale used for assessing the severity will be the CTCAE V.4.0.  
6.3.1.1  Weekly  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
6.3.1.2  Every 2 weeks  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
6.3.2  2 weeks after the end of radiotherapy  
♦ Complete physical exam (performance status)  
♦ Assessment of ASA Score (by anesthesiologist)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts (hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ 12 lead -ECG  
♦ Thoraco -abdomino -pelvic CT scan with contrast injection  if possible , and in some cases with additional 
abdomino -pelvic MRI (with IV contrast)  
♦ A second documented m ultidisciplin ary discussion to confirm that tumor is potentially resectable (anticipated 
R0/R1 resection)  
6.3.3  Surgery  
6.3.3.1  Perioperative period  
Assessment of adverse events (refer section 7.2.4 ). 
For the perioperative period (including per - and immediate postoperative periods), the scale used for assessing the 
severity will be the Dindo scale.  
Translational research: if patient consents, one blood sample of 5 mL to be collected at the ti me of surgery.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  42 / 106 September 26, 2016  6.3.3.2  The 15th day after the surgical procedure  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemi stry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  43 / 106 September 26, 2016  6.3.3.3  24 weeks after randomization  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast  (if possible) , and on indication (when CT scan is doubtful) MRI 
(with IV contrast) - Please note that this first assessment could be done very early after the surgical  
procedure in the investigational arm (see schema)  
6.3.3.4  The 60th day after the surgical procedure  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils , lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
6.3.4  Follow up period  
The follow up period starts after the day 60 th post surgery.  
Assessment of adverse events (refer section 7.2.5 ). 
For follow up period, the scale used for assessing the severity will be CTCAE V.4.0 . 
6.3.4.1  36 weeks after randomization  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast  (if possible) , and on indication (when CT scan is doubtful) MRI 
(with IV contrast)  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  44 / 106 September 26, 2016  6.3.4.2  48 weeks after randomization  
♦ Complete physical exam (perfo rmance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse events  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Cleara nce creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
♦ Thoraco -abdomino -pelvic CT scan with contrast, and on indication (when CT scan is doubtful)  MRI (with IV 
contrast)  
6.3.4.3  After 48  weeks  post randomization   
Every 6 months until recurrence or death  
The following examinations and tests will be performed:  
♦ Complete physical exam (performance status)  
♦ Cancer signs and symptoms  
♦ Assessment of all adverse  events  
♦ Thoraco -abdomino -pelvic CT scan with contrast product injections, and on indication (when CT scan is 
doubtful) MRI (with IV contrast)  
Every 12 months until recurrence or death  
The following examinations and tests will be performed:  
♦ Blood counts ( hemoglobin, white blood cells, neutrophils, lymphocytes, platelets)  
♦ Serum chemistry test (bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin)  
♦ Clearance creatinine will be calculated by Cockcroft and Gault formula ( Appendix 5) 
At 1 year and 5 years post randomization  
♦ To complete the HRQoL  checklist (refer to quality of life chapter 10) 
After recurrence  
After recurrence, the patient should be followed every 6 months for survival and further antitumo r therapy.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  45 / 106 September 26, 2016  6.4 Summary tables  
6.4.1  Surgery alone arm  
In grey : Fixed -time assessment s based on the date of randomization  
 Within 
21days 
before 
random.  During the perioperative 
period   
Follow -up period  
 
At 
surgery 
time  Day 15 
after 
surgery  60th 
day 
after 
surgery  14 wks 
after 
Random  24 w ks, 
36 wks 
& 48 
wks 
after 
rando m 48 wks after random  until 
recurrence/death  After 
recurrence 
Q 6 mo  
Q 6 
mo Q12 
mo 1 year 
post 
random  5 years 
post 
random  
Medical history  ◆           
Biopsy (a)  ◆           
Complete physical 
exam (b)  ◆  ◆ ◆ ◆ ◆ ◆     
ASA assessment  ◆           
Cancer signs and 
symptoms  ◆  ◆ ◆ ◆ ◆ ◆     
Adverse event 
assessment  ◆  
◆ ◆ ◆ ◆ ◆     
Hematology €.  ◆  ◆ ◆ ◆ ◆  ◆    
Serum chemistry 
(d) ◆  ◆ ◆ ◆ ◆  ◆    
12-lead ECG  ◆           
IV pyelogram 
(done during the 
baseline CT -scan) 
or differential 
renal isotope scan  ◆  
         
Serum or urine 
pregnancy test  ◆           
CT scan ± M€(e)  ◆ 
 within 
28 days   
  ◆ ◆ ◆     
Multidisciplinary 
discussion  ◆           
TR tissue samples  
Biopsy (FFPE ◆ ◆          
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  46 / 106 September 26, 2016  blocks and/or 
frozen tissue)  
Resected 
specimen (FFPE 
and frozen tissue)  
TR blood samples 
(5 mL each)  ◆ ◆          
HRQoL checklist  ◆        ◆ ◆  
Survival            ◆ 
a -to confirm the histological diagnosis of the tumor a biopsy may have to be performed.  
b- including performance status  
c - hemoglobin, white blood cells, neutrophils, lymphocytes, platelets  
d - bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin  
e - Thoraco -abdomino -pelvic CT scan with contra st (if iodine injection is possible) , and on indication (when CT scan 
is doubtful) additional abdomino -pelvic MRI (with IV contrast) - The baseline CT -scan will be used to assess the 
functionality of the contralateral kidney - Because the primary endpoint is local failure, CT -scan must be done until 
the diagnosis of local failure (see definition in chapter 7.1.1 ) whatever the diagnosis of metastatic r elapse.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  47 / 106 September 26, 2016  6.4.2  Radiotherapy followed by surgery arm  
In grey : Fixed -time assessment s based on the date of randomization  
 
Within 
21 
days 
before 
rando
m Preoperative period  During the perioperative period  Follow -up period  
 
Weekly  Q 2 wks  2 wks after 
the end of 
radiotherap
y At 
surgery 
time  D 15 after 
surgery  24 w ks after 
random (f)  D 60 
after 
surgery  36 & 48 wks 
after 
random  48 wks after random  until recurrence/death  After 
recurrence 
Q 6 mo  
 
 Q 6 mo  Q 12 mo  1 year 
post 
random  5 years 
post 
random  
Medical history  ◆              
Biopsy (a)  ◆              
Complete 
physical exam 
(b)  ◆ ◆  ◆  
◆ ◆ ◆ ◆ ◆     
ASA assessment  ◆   ◆           
Cancer signs and 
symptoms  ◆ ◆  ◆  ◆ ◆ ◆ ◆ ◆     
Adverse event 
assessment  ◆ ◆  ◆  ◆ ◆ ◆ ◆ ◆     
Hematology €. ◆  ◆ ◆  ◆ ◆ ◆ ◆  ◆    
Serum chemistry 
(d) ◆  ◆ ◆  ◆ ◆ ◆ ◆  ◆    
12-lead ECG ◆   ◆           
Serum or urine 
preg nancy test  ◆              
IV pyelogram  ◆              
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  48 / 106 September 26, 2016   
Within 
21 
days 
before 
rando
m Preoperative period  During the perioperative period  Follow -up period  
 
Weekly  Q 2 wks  2 wks after 
the end of 
radiotherap
y At 
surgery 
time  D 15 after 
surgery  24 w ks after 
random (f)  D 60 
after 
surgery  36 & 48 wks 
after 
random  48 wks after random  until recurrence/death  After 
recurrence 
Q 6 mo  
 
 Q 6 mo  Q 12 mo  1 year 
post 
random  5 years 
post 
random  
(done during the 
baseline CT -
scan) or 
differential renal 
isotope scan  
CT scan ± M €(e)  ◆ 
within 
28 
days    ◆  
 ◆  ◆ ◆     
Multidisciplinary 
discussion  ◆   ◆           
TR tissue 
samples  
Biopsy (FFPE 
blocks and/or 
frozen tissue)  
Resected 
specimen (FFPE 
and frozen 
tissue)  ◆    ◆          
TR blood 
samples ( 5 mL 
each)  ◆    ◆          
HRQoL checklist  ◆           ◆ ◆  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  49 / 106 September 26, 2016   
Within 
21 
days 
before 
rando
m Preoperative period  During the perioperative period  Follow -up period  
 
Weekly  Q 2 wks  2 wks after 
the end of 
radiotherap
y At 
surgery 
time  D 15 after 
surgery  24 w ks after 
random (f)  D 60 
after 
surgery  36 & 48 wks 
after 
random  48 wks after random  until recurrence/death  After 
recurrence 
Q 6 mo  
 
 Q 6 mo  Q 12 mo  1 year 
post 
random  5 years 
post 
random  
Survival               ◆ 
a - to confirm the histological diagnosis of the tumor a biopsy may have to be performed.  
b - including performance status  
c - hemoglobin, white blood cells, neutrophils, lymphocytes, platelets  
d - bilirubin, creatinine, AST, ALT, alkaline phosphatase, LDH, albumin  
e - Thoraco -abdomino -pelvic CT scan with contrast, and on indication  (when CT scan is doubtful)  with additional abdomino -pelvic MRI (with IV contrast) - The baseline CT -scan will be 
used to assess the functionality of the contralateral kidney - Because the primary endpoint is local failure, CT -scan must be done until the d iagnosis of local failure (see definition in 
chapter 7.1.1 ) whatever the diagnosis of metastatic relapse.  
f - Please note that this assessment is a fixed -time one based on the date of randomization - The two other assessments (d15 and d60) refer to t he date of the surgery. As a 
consequence the order of these 3 assessments could vary according the date of the surgery (d15, weeks 24, d60 or d15, d60 and weeks 24).  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  50 / 106 September 26, 2016  6.4.3  Collection of biological material for translational research  
Biological material  At baseline  At the time of surgery  
Tissue  Biopsy (FFPE blocks and/or, frozen 
tissue)  Resected specimen (100 -200 mg)  
(FFPE and  frozen tissue)  
Peripheral blood (EDTA tubes)  5 ml  5 ml  
7 Criteria of evaluation  
7.1 Criteria for efficacy  
7.1.1  Abdominal recurrence -free survival   
Abdominal failure free  survival will be measured from the date o f randomization (as reference) to the date of 
abdominal relapse  or death, whichever occurs first . When abdominal recurrence is equivocal (suspicio n of 
recurrence without clear -cut confirmatory image), the next planned CT -scan will be anticipated  
(2 months instead of 6 months). If the suspicious lesion grows and the diagnosis of recurrence becomes obvious, 
the date of recurrence will be the first da te with suspicion of recurrence.  
Abdominal recurrence is defined by one of the following:  
♦ Local relapse (after macroscopically complete resection)  
♦ Macroscopic residu al disease after surgery (R2)  
♦ Progressive disease during preoperative radiotherapy and/o r tumor becoming non -resectable  
♦ Peritoneal sarcomatosis (pre sence of peritoneal metastasis)  
NB: L iver metastases will be regarded as distant metastatic events, rather than abdominal recurrence . For patients 
with distant metastases they will be followed un til local failure will be detected . 
Patients without one of these events will be censored at the date of last follow -up.  
Please note that the time assessment biases inherent to this trial have been taken into account by the statistical 
analysis, neverthel ess the reference time point will be the date of randomization.  
7.1.2  Abdominal failure interval  
Abdominal failure interval  will be measured from the date o f randomization to the date of abdominal relapse  or 
death, whichever occurs first .  
Abdominal recurrence is defined  in section 7.1.1 . 
Death in absence of abdominal failure and distant metastases diagnosed before abdominal failure are not 
considered as events  for this endpoint, but will be considered as competing risk . 
Patients without one of these events will be censored at the date of last follow -up.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  51 / 106 September 26, 2016  7.1.3  Metasta ses free survival  
Metastases free  survival will be measured from the date o f randomization to the dat e of occurrence of distant 
metastases or death, whichever occurs first . Alive and metastases free patients will be censored at the date of last 
follow -up. 
7.1.4  Overall survival  
Overall survival will be measured from the date of randomization to the date of dea th, whatever the  cause. Alive 
patients will be censored at the date of last follow -up. Causes of death will be recorded and reported as a table.  
7.1.5  Tumor response to preoperative radiotherapy  
For patients receiving, preoperative radiotherapy, the tumor respo nse will be assessed using RECIST 1.1 by 
comparison of baseline CT -scan and preoperative CT -Scan.  
Objective tumor response, measured according to RECIST 1.1 ( Ref. 26), will be used as secondary end -point in this 
trial. Response criteria are essentially based on a set of measurable lesions identified at baseline as target lesions, 
and followed at the end of the radiotherapy. Response is not the primary endpoint, so a c onfirmatory CT -scan is 
not mandatory.  
Chapters 7.1.5.1 , 7.1.5.2  and 7.1.5.3  are general considerations for RECIST 1.1.  
7.1.5.1  Measurability of tumor lesions at baseline  
7.1.5.1.1  Definitions  
♦ Measurable disease - the presence of at least one measurable lesion. If the measurable diseas e is restricted to 
a solitary lesion, its neoplastic nature should be confirmed by cytology/histology  
♦ Measurable lesions -. tumor lesions  that can be accurately measured in at least one dimension ( longest  
diameter to be recorded) as ≥ 20 mm with chest x -ray, and as ≥ 10 mm with CT scan or clinical examination 
[using calipers]. Bone lesions are considered measurable only if assessed by CT scan and have an identifiable 
soft tissue component that meets these requirements (soft tissue component > 10 mm by CT sc an). Malignant 
lymph nodes  must be ≥ 15 mm in the short  axis to be considered measurable; only the short axis will be 
measured and followed. All tumor measurements must be recorded in millimeters  (or decimal fractions of 
centimeters) by use of a ruler or c alipers  
♦ Non -measurable lesions - All other lesions (or sites of disease), including small lesions are considered non -
measurable disease. Bone lesions without a measurable soft tissue component, leptomeningeal disease, 
ascites, pleural/pericardial effusions , lymphangitis cutis/pulmonis, inflammatory breast disease, lymphangitic 
involvement of lung or skin and abdominal masses followed by clinical examination are all non -measurable. 
Nodes that have a short axis <10 mm at baseline are considered non -pathologic al and should not be recorded 
or followed  
♦ Target Lesions . When more than one measurable tumor lesion or malignant lymph node is present at baseline 
all lesions up to a maximum of 3 lesions total  (and a maximum of 2 lesions per organ ) representative of all 
involved organs should be identified as target lesions and will be recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all 
involved organs, but in additio n should be those that lend themselves to reproducible repeated measurements . 
Note that pathological nodes must meet the criterion of a short  axis of ≥ 15 mm by CT scan and only the short 
axis of these nodes will contribute to the baseline sum. At baseline , the sum  of the target lesions (longest 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  52 / 106 September 26, 2016  diameter of tumor lesions plus short axis of lymph nodes: overall maximum of 3 is to be calculated and 
recorded  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  53 / 106 September 26, 2016  ♦ Non -target Lesions . All non -measurable lesions (or sites of disease) including pathological nodes (tho se with 
short axis ≥ 10 mm but < 15 mm), plus any measurable lesions over and above those listed as target lesions are 
considered non-target lesions . Measurements are not required but these lesions should be noted at baseline 
and should be followed as “pre sent” or “absent”  
All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more 
than 28 days before randomization . 
7.1.5.2  Methods of measurement  
The same method of assessment and the same technique should be used  to characterize each identified and 
reported lesion at baseline and during follow -up. Assessments should be identified on a calendar schedule and 
should not be affected by delays in therapy, which may be treatment arm dependent. While on study, all target  
lesions recorded at baseline should have their actual measurements recorded on the CRF at each subsequent 
evaluation, even when very small (e.g. 2 mm). If it is the opinion of the radiologist that the lesion has likely 
disappeared, the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly 
seen but too small to measure, a default value of 5 mm should be assigned. For lesions which fragment/split add 
together the longest diameters of the fragmented portions; for lesio ns which coalesce, measure the maximal 
longest diameter for the “merged lesion”.  
♦ Clinical Lesions . Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm as 
assessed using calipers (e.g. skin nodules). For the case of ski n lesions, documentation by color photography 
including a ruler to estimate the size of the lesion is recommended. If feasible, imaging is preferred.  
♦ Chest X -ray. Chest CT is preferred over chest X -ray, particularly when progression is an important endpoin t, 
since CT is more sensitive than X -ray, particularly in identifying new lesions. However, lesions > 20 mm on chest 
X-ray may be considered measurable if they are clearly defined and surrounded by aerated lung.  
♦ CT, MRI . CT is the best currently available and reproducible method to measure lesions selected for response 
assessment. This guideline has defined measurability of lesions on CT scan based on the assumption that CT 
slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 m m, the minimum size for a 
measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g. for body 
scans). While PET scans are not considered adequate to measure lesions, PET -CT scans may be used providing 
that the  measures are obtained from the CT scan and the CT scan is of identical diagnostic quality to a 
diagnostic CT (with IV and oral contrast).  
♦ Ultrasound.  Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement. If new lesions are identified by ultrasound in the course of the study, confirmation by CT should 
be obtained.  
♦ Endoscopy, Laparoscopy . The utilization  of these techniques for objective tumor evaluation is not advised. 
However, they can be useful to confirm complete pathological response when biopsies are obtained or to 
determine relapse in trials where recurrence following complete response or surgical resection is an endpoint.  
♦ Tumor Markers . Not applicable for this study. Cytology, Histology . These techniques can be used to 
differentiate between PR and CR in rare cases if required by protocol (for example, residual lesions in tumor 
types such as germ ce ll tumors, where known residual benign tumors can remain). When effusions are known 
to be a potential adverse effect of treatment (e.g. with certain taxane compounds or angiogenesis inhibitors), 
the cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment 
when the measurable tumor has met criteria for response or stable disease is advised to differentiate between 
response or stable disease and progressive disease.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  54 / 106 September 26, 2016  7.1.5.3  Tumor response evaluation  
All patients will have their BEST RESPONSE from the start of study treatment until the end of treatment classified 
as outlined below:  
Complete Response  (CR): disappearance of all target  and non-target  lesions and normalization of tumor markers. 
Pathological ly mph nodes must have short axis measures < 10mm ( Note : continue to record the measurement 
even if < 10 mm and considered CR). Tumor markers must have normalized. Residual lesions (other than nodes < 
10 mm) thought to be non -malignant should be further inves tigated (by cytology or PET scans) before CR can be 
accepted.  
Partial Response  (PR): at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and 
short axis measure for nodes) of target lesions, taking as reference the baseline s um of diameters. Non target 
lesions must be non -PD.  
Stable Disease  (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as 
reference the smallest sum of diameters on study.  
Progressive Disease  (PD): at leas t a 20% increase in the sum of diameters of measured lesions taking as references 
the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥ 5 mm. 
Appearance of new lesions will also constitute PD (including lesions in previously unassessed areas). In exceptional 
circumstances, unequivocal progression of non -target disease may be accepted as evidence of disease progression, 
where the overall tumor burden has increased sufficiently to merit discontinuation of treatment , for example 
where the tumor burden appears to have increased by at least 73% in volume (which is the increase in volume 
when all dimensions of a single lesion increase by 20%). Modest increases in the size of one or more non -target 
lesions are NOT consid ered unequivocal progression. If the evidence of PD is equivocal (target or non -target), 
treatment may continue until the next assessment, but on further documentation, the earlier date must be used.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  55 / 106 September 26, 2016  Table 1: Integration of Target, non -Target and New lesi ons into response assessment:  
 
Target Lesions  Non -Target Lesions  New 
Lesions  Overall 
Response  Best Response for this category 
also requires  
Patients with Target lesions ± non target lesions  
CR CR No CR Tumor nodes < 10 mm  
CR Non -CR/Non -PD No PR 
 CR Not all evaluated  No PR 
PR Non -PD/ not all 
evaluated  No PR 
SD Non -PD/ not all 
evaluated  No SD documented at least once ≥ 
4 wks from baseline  
Not all evaluated  Non -PD No NE  
PD Any Any  PD  
Any PD Any PD  
Any Any Yes PD  
Patients with Non target lesions ONLY  
No Target  CR No CR All tumor nodes < 10 mm  
No Target  Non -CR/non -PD No Non -CR/ 
non-PD  
No Target  Not all evaluated  No NE  
No Target  Unequivocal PD  Any PD  
No Target  Any Yes PD  
Note : Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression [or evidence of unequivocal disease progression] at 
that time should be reported as “ symptomatic deterioration ”. This is a reason for st opping the rapy, but 
is NOT objective PD. Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  56 / 106 September 26, 2016  7.1.5.4  Reporting of tumor  response  
All patients included in the study must be assessed for response to treatment, even if there is a major protocol 
treatment deviation or if they are ineligible , or not followed/re -evaluated . Each patient will be assigned one of the 
following categories: complete response, partial response, stable disease, progressive diseas e, early death or not 
evaluable . 
Early death is defined as any death occurring before the first per protocol time point of tumor re -evaluation.  
Patients’ response will be classified as "not evaluable" if insufficient data were collected to allow evaluation  per 
these criteria.  
7.2 Evaluation of toxicity  
7.2.1  Adverse events  
All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable 
possibility, no reasonable possibility) and this assessment will be recorded in t he database for all adverse events.  
Only the worst grade per category of event will be recorded per  period of treatment.  
The collection period will start from  randomization until death of all patients.  
7.2.2  Scales for toxicity evaluation  
For practical reasons, the description of safety/complications will follow the following rules:  
7.2.2.1  Preoperative period  
The preoperative period will begin from the date of randomization to the date of the surgical procedure. During 
this period, the expected events will be related m ainly to the radiotherapy treatment (acute radiotherapy -
related toxicity). As a consequence, events (see list below 7.2.3 ) will be graded according to the CTCAE Ve rsion 
4.0.  
7.2.2.2  Perioperative period (including per - and immediate postoperative periods)  
This perioperative period will begin at the time of anesthesia induction (date of surgery) and will end at the 60th 
day following the surgical procedure. The per ioperati ve period will begin at the time of anesthesia induction and 
will end at the time of complete closure of the wound. The immediate postoperative period will begin at the 
time of complete closure to the wound and will end the 60th day following the surgical procedure. The main 
expected events will be related to the surgical procedure. Some events could be also the consequence of prior 
radiotherapy or the combination of both treatments. During this period, we will use the Dindo scale ( Ref. 27).  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  57 / 106 September 26, 2016  Grade  Definition  
Grade I  Any deviation from the normal postoperative course without the need for pharmacological 
treatment or surgical, endoscopic, and radiological interventions  
Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics, 
electrolytes, and physiother apy. This grade also includes w ound infections opened at bedside.  
Grade II  Requiring pharmacological treatment with dru gs other than such allowed for grade I 
complication. Blood transfusions and total parenteral nutrition are also included.  
Grade III  Requiring surgical, endoscopic or radiological intervention.  
Grade IV  
 Life-threatening complication (including CNS complications*) requiring IC/ICU management  
Single -organ or multi -organ dysfunction (including dialysis)  
 
Grade V  Death of the patient  
* Brain hemorrhage, ischemic stroke, subarrachnoidal  bleeding, but excluding transient ischemic attacks  
7.2.2.3  Follow -up period  
This period will start after the 60th day following the surgical procedure. The main expected toxicities will be 
related to surgery or radiotherapy (late toxicity). So we will use the  CTCAE Version 4.0 for coding and grading 
these events  (see list 7.2.5 ). 
7.2.2.4  Summary   
Periods  Preoperative  Perioperative  Follow -up 
Guidance for SEVERITY 
assessment  CTCAE V4.0  Adapted from Dindo et al.  
(Ref. 27) CTCAE V4.0  
Guidance for causality 
assessment  Clinical judgment and literature data  (related to radiotherapy, related to surgery, 
related to both treatments and other cause)  
7.2.3  Safety during the preoperative period  
This study will use the International Terminology Criteria for Adverse Events (CTCAE), version 4.0 for radiation -
related adverse event reporting. A copy of CTCAE can be accessed  on the CTEP home page 
(http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/ctc.htm ). A link to this page is provided on 
the EORTC web site ( http://www.eortc.be/ ; if location is moved to another site, this link will be updated.  
Planned safety analysis and tabulations are described in the statistics section.  
Toxicity that appears during the preoperative period will be graded as acute radiation  related toxicity. The 
following toxicities are expected:  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  58 / 106 September 26, 2016  ♦ General disorders and ASC - Fatigue grade 3  
♦ Gastrointestinal disorders - Constipation grade ≥ 3  
♦ Gastrointestinal disorders - Diarrhea grade ≥ 3  
♦ Gastrointestinal disorders - Nausea grade ≥ 3  
♦ Gastrointestinal  disorders - Vomiting grade ≥ 3  
♦ Injury, poisoning and procedural complications - Dermatitis associated with radiation, grade ≥ 3  
♦ Investigations - Creatinine increase grade ≥ 3   
♦ Investigations - Weight loss grade ≥ 3  
♦ Metabolism and nutrition disorders - Anor exia ≥ 3  
♦ Nervous system disorders - Myelitis grade ≥ 2  
7.2.4  Safety during the perioperative period  
7.2.4.1  "Surgical complications"  
During this period, a dverse events and side effects either directly or indirectly related to surgery and its sequelae  
can be attributed  to general premedication/anesthesia required to perform surgical procedure  or to the surgical 
procedure itself. Some events could be related to the radiotherapy.  
In exceptional cases, preme dication or anesthesia may result in a delay or an inability to perform the planned 
surgical procedure . These instances have also to be recorded in the CRF.  
The perioperative  period will commence at the time of surgery (at the time of the induction anesthe sia) to the 
complete closure of the wound. The main expected per operative adverse events are :  
♦ massive hemorrhage  
♦ fistulae  
The postoperative  period will commence at complete closure of the wound until the 60 days post -surgery. The 
main expected post operati ve adverse events  are: 
♦ postoperative hemorrhage/bleeding  
♦ anastomotic insuffi ciency (with risk of peritonitis, digestive fistula, pancreatic fistula, bile leakage)  
♦ infected postoperative collection and surgical site infection  
♦ intestinal occlusion  
♦ limb co mpartmental syndrome  
♦ Wound dehiscence  
All complications requiring re -operation or per cutaneous drainage have to be considered as SAE.   
Description of perioperative  care  
The description of perioperative  care will be based on the following key parameters.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  59 / 106 September 26, 2016  ♦ During the per ioperative period:  
♦ duration of surgery (in minutes: from the incision to the complete closure of the wound) - 
♦ number of administered Red Blood Cell (RBC) units during surgical procedure  
♦ number of administered Platelet (PLT) units during surgical procedure  
♦ number of administered Fresh Frozen Plasma (FFP) units during surgical procedure  
♦ During the immediate postoperative period:  
♦ duration of hospitalization (from the entry to surgery unit to  discharge; including the time spent in 
secondary care unit)  
♦ duration of hospitalization in intensive care units  (from the entry to the surgery unit to discharge from 
the intensive care unit). The cause of hospitalization in intensive care units will be r ecorded i.e.: patient 
status or local organization.  
♦ reoperation  rate within 60 days after the initial surgery (and reason for this surgical procedure)  
♦ readmission  rate within 60 days after the initial surgery and reason for this admission  
7.2.5  Late toxicity  
Late toxicity (after the 60th day following the surgical procedure) will be evaluated and graded, if possible, 
according to the CTCAE version 4.0. Particular attenti on will be given to the following events (alphabetical order):  
♦ Gastrointestinal disorders - Colonic fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Colonic stenosis - Grade ≥ 2  
♦ Gastrointestinal disorders - Constipation grade ≥ 3  
♦ Gastrointestinal disorde rs - Diarrhea - Grade ≥ 3  
♦ Gastrointestinal disorders - Gastro -intestinal fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Enterovesical fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Ileal fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Ileal stenosis - Grade ≥ 2  
♦ Gastrointestinal disorders - Jejunal fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Jejunal stenosis - Grade ≥ 2  
♦ Gastrointestinal disorders - Rectal fistula - Grade ≥ 2  
♦ Gastrointestinal disorders - Small intestinal stenosis - Grade ≥ 2  
♦ Gastroi ntestinal disorders - Small intestinal perforation - Grade ≥ 2  
♦ General disorders and ASC - Fatigue grade 3  
♦ Hepatobiliary disorders  - Hepatic failure - Grade ≥ 3  
♦ Investigations - Creatinine increase - Grade ≥ 2  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  60 / 106 September 26, 2016  ♦ Investigations - Weight loss grade ≥ 3  
♦ Metabolism and nutrition disorders - Anorexia ≥ 3 
♦ Nervous system disorders - Myelitis - Grade ≥ 2  
♦ Nervous system disorders - Peripheral sensory neuropathy - Grade ≥ 3  
♦ Nervous system disorders - Peripheral motor neuropathy - Grade ≥ 3  
♦ Neoplasms benign, mali gnant and unspecified - Treatment related secondary malignancy - Grade ≥ 3  
♦ Vascular disorders - Hypertension (arterial hypertension) - Grade ≥ 3  
7.2.6  Serious adverse events  
Serious adverse events are defined by the Good Clinical Practice Guideline.  
SERIOUS ADV ERSE EVENTS SHOULD BE IMMEDIATELY REPORTED ACCORDING TO THE PROCEDURE DETAILED IN 
THIS PROTOCOL  (see chapter on Reporting Serious Adverse Events).  
7.2.7  Toxic deaths  
Toxic death is defined as death due to toxicity (defined as adverse events at least with reasona ble possibility 
related to study treatment). The cause of death must be reported as "toxicity".  
The evaluation of toxic deaths is independent of the evaluation of response (patients can die from toxicity after a 
complete assessment of the response to study  treatment).  
7.2.8  Evaluability for safety  
All patients who have started the treatment will be included in overall safety analyses.  
Patients who have discontinued treatment because of toxicity will always be included in the toxicity analyses.  
8 Statistical conside rations  
8.1 Statistical design  
8.1.1  Sample size  
The primary endpoint of this trial is "abdominal" recurrence free survival (see chapter 7.1.1  for definition). The trial 
is designed as a randomized phase III trial. The control arm is curative -intent surgery alone without neo -adjuvant 
radiotherapy. The experimental group is preoperative radiotherapy plus surgery.  
The primary trial objective is to test the null hypothesis (H0) of no difference against the alternative of a difference 
in abdominal recurrence free survival between the two groups. The number of events and sample size is 
determined to provide 90% power of rejecting the null hypothesis of no difference against the alt ernative of a 20% 
difference in the abdominal recurrence free survival rate at 5 years (from 50% in the control group to 70% in the 
experimental group or alternatively a shift in median from 5 years in the control group to 9.7 years in the 
experimental tre atment group, HR = 0.52), at a global 2 -sided 5% significance level assuming that abdominal 
recurrence free survival follows an exponential distribution in both groups.  
This test requires that 102 events be observed at the time of the final statistical ana lysis. Events may be a local 
relapse (after macroscopically complete resection), macroscopic residue after surgery (R2) or progressive disease 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  61 / 106 September 26, 2016  during the preoperative radiotherapy and/or tumor becoming non -operable or not resected or a "peritoneal 
sarcomat osis" (presence of peritoneal metastasis).  
It is estimated, using EAST ® version 5.3 (Cytel Inc) that if 256 patients are randomized during 39 months, 102 
events should be observed approximately 41 months after the entry of the last randomized patient in th e study 
under H1.  
8.1.2  Randomization and stratifications  
Patients will be centrally randomized (for practical details, see chapter on randomization procedure). A 
minimization technique will be used for random treatment allocation stratifying by institution and performance 
status (0 -1 vs 2).  
8.2 Interim analyses  
Two early safety checks will be p erformed in each treatment arm after 33 and then after 66 patients have been 
treated  in each group . This review will be based on monitoring the rate of non-operable tumors  and the rate of 
reoperation (morbidity).  If the observed toxicity rate approaches the limits set, the EORTC Data Safety Monitoring 
Board , a subcommittee of  the EORTC IDMC , will be contacted  for a recommendation whether the study needs t o 
be amended or stopped. A list of SAEs for the radiotherapy arm will be provided.  
The difference s between randomized groups used for the stopping rules  will be based on the number of patients 
who are non operable or require reoperation. The stopping rule s are defined according to an alpha -spending 
function of the gamma family (Ref. 28) with gamma parameter = -1 and  are the following:  
♦ Morbidity: rate of reoperation >20%  difference  
The comparisons are done between randomized groups. Assuming that the  rate of reoperation in the reference 
arm is 18%, t he probability to observe a n absolute increase  of 20%  in the experimental arm  when in fact the rates 
are identical in both r andomized groups is ≤ 0.0378 (type I) at the first look and ≤0.01  at the second look . The 
probability  of observing a difference >20% when the true difference is 30% is > 0.84  (power) at the first look .  
♦ Rate of no n-operable tumors >12% difference  
The compari sons are  done between randomized groups with a one -sided test.  Assuming that the event rate in the 
reference arm is 2%, the probability to observe an absolute increase of 12% in the experimental arm when in fact 
the rates are identical in both randomized groups is ≤0.0378 (type I) at the first look and ≤ 0.01  at the second look.  
The probability  of observing a difference > 12% when the true difference is 20% is > 0.90  (power) at the first look .  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  62 / 106 September 26, 2016  8.3 Statistical analysis plan  
8.3.1  Primary and s econdary endpo ints 
The endpoints that will be used in the statistical analysis are defined in chapter 7. 
The primar y endpoint will be "abdominal recurrence free survival ". 
The s econdary endpoints measuring treatment efficacy are:  
♦ Metastasis -free survival  
♦ Overall survival  
♦ Abdominal failure interval  
♦ Tumor response to preoperative radiotherapy  
The secondary endpoints measuring treatment toxicity are: 
♦ Acute toxicity profile in the p reoperative period (from the date of randomization to the date of surgical 
procedure)  
♦ Perioperative complications (from date of surgery today 60 following surgery)  
♦ Late complications (after day 60 following surgery)  
8.3.2  Analysis populations  
♦ Intention -to-treat population: a ll randomized patients will be analyzed in the arm they were allocated by 
randomization  
♦ Per protocol population: all randomized patients who are eligible and have started their allocated treatment 
(at least have been operated or received one f raction of irradiation)  
♦ Safety population : all randomized patients who have started their allocated treatment (have at least been 
operated or received one fraction of irradiation)  
♦ RT Safety population: patients in the safety population who received at least one fraction of irradiation  
♦ Surgical safety population: patients in the safety population who have been operated  
♦ Complete safety population: patients in the safety population who received their allocated treatment 
(have at least been operated and rec eived one fraction of irradiation in the experimental arm)  
A patient will be considered to be eligible  if he/she did not have any deviation from the patient entry criteria listed 
in chapter 3 of the protocol. Potential e ligibility problems will be assessed by the Clinical Research Physician at 
time of medical review . 
8.3.3  Statistical methods  
The primary analys is of all efficacy endpoints  will be performed in the intention -to-treat population.  
The analysis of the toxicity  endpoints will be performed in the safety populati on: 
♦ the analysis of acute and late toxicity of radiotherapy will be performed in the RT safety population  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  63 / 106 September 26, 2016  ♦ the analysis of the surgical complications (within 60 days after surgery) will be performed in the surgical safety 
population  
♦ the analysis of late t oxicity will also be performed in the complete safety population  
The Serious Adverse Events are always reported for all patients who entered the study.  
8.3.3.1  Main a nalysis of the efficacy endpoints  (primary and secondary)  
A 2-sided 5% significance level will be  applied to all tests and 95% confidence intervals will be constructed.  
Abdominal recurrence free survival, metastatic free survival and overall survival will be described using Kaplan -
Meier curves ( Ref. 29) in the two treatment arms. The median survival time and its associated non -parametric 
confidence interval will be calculated.  
For analysis purposes:  
Immediate surgery arm: any abdominal recurrence occurring after surgery prior to the week 14 will be counted as 
occurring at week 14 (+/ - 1 week) and any progression occurring after the week 14 will be counted as occurring at 
week 24.  
Deferred surgery arm: any abdominal recurrence occurring prior to surgery will be cou nted as occurring at week 14 
and any abdominal recurrence occurring after surgery and prior to or during the week 24 will be counted as 
occurring at week 24.  
Abdominal failure interval will be described using cumulative incidence curves ( Ref. 30). Cumulative event rates at 
3 years and at 5 years will be documented, and their confidence interval will be calculated using the normal 
approximation.  
All efficacy endpoints wi ll be compared between the randomized groups using the Cox’s proportional hazards 
model ( Ref. 31). For the competing risk endpoints (incidence of distant metastases) this will be a cause specific 
Cox's proportional hazards model.  
8.3.3.2  Analysis for Safety endpoints  
8.3.3.2.1  Acute toxicity profile of preoperative radiotherapy  
The acute toxicity will be assessed according to the NCI -CTC version 4.0 in the RT safety population. For each  item 
of the CTCAE, the worst grade of acute toxicity will be tabulated. A table will present patients who will not receive 
radiotherapy and the associated reason.  The main items investigated during the preoperative period  are defined in 
chapter 7.2.3 .  
8.3.3.2.2  Perioperative complications  
In this part, we would like to investigate whether the RT increases the complications occurring due to surgery.  
A first table will list patients in the ITT population who were not operated and provide the associated reason 
according to treatment arm.  
Other analyses will be performed in the surgical safety population taking into account all events occurring  during 
the perioperative period (as defined in section  7.2.2.2 ). Adverse events and side effects possibly related to surgery 
will be assessed according to the Din do's classification ( Ref. 27). For each item, the frequency of the worst grade of 
the observed toxicity will be tabulated by treatment group.  
The main items investigated during the perioperative period  are defined in chapter 7.2.4 .  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  64 / 106 September 26, 2016    
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  65 / 106 September 26, 2016  8.3.3.2.3  Late toxicity of preoperative radiotherapy (>60 days after the surgery)  
The late toxi city occurring more than 60 days after surgery will be tabulated by treatment group.  
The cumulative risk for patients to have late treatment side effects  (as defined in section 7.2.5 ) will be estimated  
using cumulative incidence curves ( Ref. 32). Cumulative event rates at 3 years and at 5 years will be estimated , and 
their 95% confidence interval will be calculated. In these analyses, the time to the occurrence of a specified severe  
late adverse event is defined as the time counted from randomization to the first reported late (≥60 days after last 
treatment) adverse event grade ≥3, with censoring at the time of last examination prior to the clinical  cut-off date  
for patients who did not report any such events. Patients without the event of interest who start a new treatment 
or die will be considered in the analysis a s having had a competing risk. Time to event c omparisons between the 
randomized groups will be performed using the Cox’s  proportional hazards model ( Ref. 31). The analysis will be 
carried out for each side effect separately and for the time to first occurrence of the late side effects regrouped in 
SOC.  
The risks of late treatment toxicity that is present at 3 years (respectively 5 years) after randomization will be 
estimated from the cumulative incidence curves.  
8.3.4  Pre-planned sensitivity or exploratory analyses  
The statistical analyses of  the efficacy endpoints specified in chapter 7 will be repeated in the per protocol  
population  only if 10% of the patients have been excluded from the per -protocol populations .  
Furthermore, the efficacy endpoints will also be analyzed in regression models including important prognostic 
factors.  
8.3.5  Data recoding and display  
Frequency tables will be tabulated (by treatment group or otherwise) for all categorical variable s by the levels of 
the variables as they appear on the CRF (with %). Categories with a text field specification will be tabulated as 
categories and then supplemented by a listing with the following information for the patients fulfilling the 
condition for the specification (patient id, institution, treatment group, value of the item and text field contents).  
Dates relating to events prior to entry will be presented as the delay in days (or weeks, months, or years) between 
the past event and the date of entr y (date of randomization – date of past event + 1) and presented using the 
median and range. For example, on the randomization checklist, the date of last administration of prior treatment 
(or the date of first diagnosis of the cancer) will be presented as  the time elapsed (in days, weeks, months or years, 
as appropriate) since the day of the last administration and the date of entry on study (date of randomization – last 
administration/diagnosis +1).  
Other delays (eg. re -treatment delays) are presented as continuous variables using the median and range.  
Continuous variables for which a coding system exists (such as for laboratory data) will be recoded into categories 
(for adverse events, the grading scale specified in the protocol will be used). Whenever no  specific scale exists, lab 
data will be categorized based on the normal range: for example, below the lower normal limit (when 
appropriate), within the normal range, above the upper limit  of normal (U LN) and the degree to which it is above 
the U LN (for ex ample > 2.5 x U LN, > 5 x U LN, > 10 x U LN). For laboratory data, the nadir is generally displayed. The 
nadir in a given cycle is the lowest laboratory value in that cycle; the overall nadir for a patient is the lowest 
laboratory value among all cycles.  
Other continuous v ariables (for example age, dose)  are presented using the median and range (minimum, 
maximum).  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  66 / 106 September 26, 2016  If appropriate, continuous data may also be presented in categories (for example, age may also be grouped in 
decades).  
8.4 End of study  
End of study occurs when all of the following criteria have been satisfied:  
1. Thirty days after all patients have stopped protocol treatment  
2. The trial is mature for the analysis of the primary endpoint as defined in the protocol  
3. The database has been f ully cleaned and frozen for this analysis  
9 Data Monitoring  
Safety data are reviewed within the EORTC Headquarters on a regular basis as part of the Medical Review  process. 
Problems which are identified will be discussed with the Study Coordinators who will take  appropriate measures. 
Safety information will also be included in trial status reports which serve as a basis  of discussion during EORTC 
Group meetings. These reports will be made available to investigators  participating in the study.  
The EORTC Data S afety Monitoring Board (DSMB), a subcommittee of the EORTC Independent Data  Monitoring 
Committee (IDMC), will review all safety problems identified by the EORTC Headquarters  for which an advice is 
sought. This DSMB has early trials/drug development experti se and will provide a  separate review process, having 
no access to outcome data. The EORTC DSMB will be primarily for  phase I and non randomized phase II studies, but 
will also provide recommendations as an initial step in  phase III trials to advise if the  study should then go to the 
full IDMC.  
The EORTC IDMC is charged with the interim review (planned or not planned) of randomized phase II  and phase III 
studies. When interim analyses are carried out, the interim monitoring of efficacy and safety  data is pe rformed 
according to the Statistical Considerations chapter in this protocol and EORTC Policy  004 on “Independent Data 
Monitoring Committees and Interim Analyses”.  
The results of the interim analyses are confidential and are discussed by the EORTC IDMC. The IDMC  will 
subsequently recommend to the EORTC Group whether any changes should be made to the study.  
No efficacy results will be presented at EORTC Group meetings or elsewhere before the trial is closed to  
recruitment and the data are mature for the analysis of the primary endpoint, unless recommended  otherwise by 
the EORTC IDMC.  
10 Quality of life assessment  
10.1 Rationale  
Reducing mortality and morbidity is still the most important factor in clinical research. Nevertheless, issues such as 
reducing si de effects, symptom relief and improving patients’ satisfaction have also become relevant parameters in 
the evaluation of medical strategies. The rationale for measuring HRQoL in this study is in measuring long -term 
impact related to surgical complication on patients’ well -being.  
The following issues were identified to be of interest:  
♦ Fatigue  
♦ Mobility (difficulty to walk, risk of falling with or without fracture)  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  67 / 106 September 26, 2016  ♦ Digestive troubles (occlusion)  
♦ Sexual disorders  
♦ Pain  
10.2 HRQoL instruments  
The EORTC QLQ -C30 is a w ell-validated 30 -item scale that assesses the overall HRQoL of cancer patients ( Ref. 40). 
It is composed of six functional scales (physical, role functioning, emotiona l functioning, cognitive functioning, 
social functioning, and global health status/QoL) and nine symptom scales/items (fatigue, nausea and vomiting, 
pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). However this in strument 
is aimed at evaluating cancer therapies in general and contains many domains not of particular interest to this 
study. Therefore only the following domains will be kept:  
♦ Physical functioning  
♦ Role functioning  
♦ Social functioning  
♦ Pain  
♦ Fatigue  
♦ Appetit e loss  
♦ Global health status/QoL  
In addition, the following domains of interest from existing QLQ modules will be added to complement to scope of 
the questionnaire:  
♦ Stomach Pain (STO22 module)  
♦ Have you had discomfort when eating?  
♦ Have you had pain in your s tomach area?  
♦ Have you had discomfort in your stomach area?  
♦ Sexual interest, Impotence (male), Dyspareunia (female) (CR29 module)  
♦ To what extent were you interested in sex?  
♦ Did you have difficulty getting or maintaining an erection?  
♦ Did you have pain or discomfort during intercourse?  
These questions are taken from validated questionnaires in such a way as to preserve their inner scale structure. 
The respective questionnaires are  the STO22 module ( Ref. 41) and the CR29 module ( Ref. 42). 
Although the resulting HRQoL checklist is not a validated instrument,  it is an ad -hoc instrument optimized for this 
specific setting and composed of integral parts of validated HRQoL questionnaires.  See Appendix 9 for the English 
versi on of this checklist.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  68 / 106 September 26, 2016  10.3 Study design  
10.3.1  Timing of assessment  
In both treatment arms, HRQoL should be assessed using the HR QoL checklist as described in 6.2 according t o the 
following schedule: The baseline assessment needs to be collected not earlier than 3 weeks before randomization, 
but before the start of the protocol treatment. This assessment is preferably done before the randomization but 
can be performed before, during or shortly after randomization.  
Two subsequent assessments will be performed at 1 and 5 years after randomization. Time windows for these 
assessments will be (+/ -) 3 month around the scheduled visit. If a patient progresses or withdraws from the stu dy, 
QoL should no longer be assessed.  
 HRQoL checklist Assessment  Eligible time window  
T0 Baseline  From 3 weeks before randomization until 
start of treatment or patient knowledge of 
randomized treatment arm  
T1 Year 1  Up to 3 months before or after.  
T2 Year 5  Up to 3 months before or after.  
10.3.2  HRQoL data collection  
HRQOL checklists must be filled out at the hospital when the patient comes in for a scheduled visit. The checklists 
will be handed out to the patients by the investigator or a study nurse prior to seeing the doctor for clinical 
evaluations. Patients will be asked to fill out the checklists as completely and accurately as possible. Master copies 
(and appropriate translations) of the checklist will be sent to the institution together with the CRFs.  The clinical 
forms will include a question about whether the HRQoL forms have been filled in and if not, the reason why. Data 
collection procedures should be followed using the EORTC guidelines in  Appendix 7. 
10.3.3  Missing data  
Missing data may hamper assessment of HRQoL in clinical trials. This may be because centers do not collect the 
checklists at the appropriate time (unit non -response), and becaus e patients may miss questions within the 
checklists (item non -response). The latter problem occurs less than 2% on average and should not be a problem. 
The former problem will be minimized by ensuring that participating centers are properly informed and mo tivated 
towards HRQoL assessment. Compliance will be calculated as the number of forms correctly received according to 
the schedule described in the previous section over the number of forms expected. During the study, compliance 
with completing QoL checkl ists will be investigated at each time point. The compliance of the HRQoL assessments 
will also be reviewed twice a year and will be a part of the descriptive report by the EORTC Headquarters for the 
Group's plenary sessions.  
10.4 Statistical considerations  
10.4.1  Sample size  
The sample size calculation for this study has been performed based on the primary endpoint (see chapter 8). A 
difference of 10 points on a 100 point scale between the two treatment arms will be considered as clinically 
significant ( Ref. 43). The standard deviation of the global QoL scale is approximately 20 points. With a minimal 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  69 / 106 September 26, 2016  effect size of 0.5 (i.e. one -half standard deviation), with alpha set at 0.05 and beta at 0.20 (power 0.80), a minimum 
of 64 patien ts per treatment arm is required.  
It should be noted that at the 5 year time point (T2) about 60% of the patients are expected to have dropped out 
due to PD or death. So the effective sample size for the 5 year time point will be about 150 patients, disco unting 
patient compliance.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  70 / 106 September 26, 2016  10.4.2  Primary HRQoL endpoint and hypothesis  
The primary HRQoL endpoints considered relevant to this trial are listed in the objectives. These correspond to the 
following scales:  
♦ Fatigue  
♦ Physical function  
♦ Stomach Pain, Appetite Loss  
♦ Sexual Interest, Impotence, Dyspareunia  
♦ Pain  
All these scales will be comparatively analyzed between the two treatment arms . 
10.4.3  Method for statistical analysis  
Summary statistics will be calculated to assess the change from the baseline score to the year 1 (T1 ) and year 5 (T2) 
assessment respectively. Absolute change in score will be compared via non -parametric logrank tests. In addition, 
the changes in scores will be further summarized into categorical responses based on in/decrease of 10 points 
from baseline.  The 10 point change corresponds  to a clinical relevant change for the EORTC QLQ -C30 ( Ref. 43). 
Two -sided tests at 5% significance level will be used. No correction fo r multiplicity will be made but statistical 
significance will be contrasted with clinical significance in order to avoid inflation of false positive results.  
Missing data will be taken into account via sensitivity analysis where missing scores will be impu ted under different 
assumptions. The sensitivity analyses will only be used to help interpret effects observed during the primary 
analysis. The results from these analyses should however not take priority over the main analysis.  
11 Translational research  
11.1 Introduction  
This trial provides a unique opportunity  to perform a translational research project and  to collect biological 
material (prospective biobanking for future research) in both arms (previously irradiated and non irradiated 
tissues). Basically the pri mary aim of the planned translational research  is to establish new prognostic factors in 
patients with RPS, especially liposarcoma. The potential events of interest are:  
♦ MDM2 status explored by fluorescence in situ hybridization, real -time quantitative reverse transcription PCR 
and immunohistochemistry (Ref. 34, Ref. 35, Ref. 36) 
♦ status of the CCDN1/CDK4/P16INK4a/RB1/E2F pathway explored by fluorescence in situ  hybridization, real -
time quantitative reverse transcription PCR and immunohistochemistry (Ref. 33) 
♦ HMGCOA status explored by fluorescence hybridization in situ (Ref. 33) 
♦ Carboxypeptidase M expression explored by fluorescence in situ hybridization (Ref. 37) 
♦ C-jun and ASK1 status explored by fluorescence in situ hybridization (Ref. 38) 
♦ Investigation of factors for predicting outcome of radiotherapy and side effects related to  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  71 / 106 September 26, 2016  To investigate all these issues, genomic and gene expression profiling will be performed from samples before and 
after radiotherapy (for patients randomized in the radiotherapy arm) . Genomic profiling of tumor and 
constitutional DNA will be performed using SNP array, allowing us to test whether there is an association between 
the genomic profile and response to radiotherapy.  
To maximize the development of future research program, we strongly recommend storing fresh frozen large 
samples of surgically removed tissues.  
11.2 Informed consent  
Patients will be eligible for the prospective biobanking  if they are eligible for the clinical trial and have given their 
written informed consent to par ticipate to this program.  
All patients included in the clinical study will be offered to participate to the associated translational research 
project defined in section 11.1  and the prospective bio -banking of biological material at the time they are offered 
participation to the clinical study. Patients will have the possibility to accept or refuse participation to the 
translational research project and to the  prospe ctive bio -banking for future research.  
If patient accepts to join, a specific consent form must be signed.  
11.3 Human b iological material  
The Human Biological Material (HBM) will be large  samples of surgical specimens and blood samples.  
Biological materials  At baseline  At the time of surgery  
Tumor tissue  Biopsy ( FFPE blocks and/or frozen 
tissue ) Resected specimen (100 -200 mg)  
(FFPE and frozen tissue)   
Peripheral b lood  (EDTA tubes )  5 ml  5 ml   
Store frozen tissue and blood at -80° 
11.4  General principles for human biological material collection  
Human biological material collection  involves the collection and storage of biological material , residual biological 
material or derivatives in  compliance with ethical and technical requirements .  
In this study, biological material will be stored at each institution until the identification of a Biobank that will 
centrally store this material. After identification of the biobank and approvals of the Ethics committees, the 
biological material will b e shipped to this central biobank. From  here, the biological material will be  used or  
distributed to the o ther research laboratories involved in the translational research (TR) projects defined in the 
future .  
The following principles apply to storage of HBM:  
♦ The collected HBM should be documented, i.e. the amount remaining and its location.  
The Study Steering Committee (SSC)/Group committee  will be responsible for TR project review and prioritization, 
including the consideration of newly propos ed TR projects not specified in the protocol. In the absence of a SSC,  
responsibilities of the SSC are transferred to the Group and/ or EORTC HQ as applicable.  
Final decisions on  the use of HBM will be determined by a majority vote of the SSC/Group committ ee. Additional 
expertise may be sought through advisory non -SSC/Group committee  members.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  72 / 106 September 26, 2016  Access to HBM  (see EORTC Biobanking Policy POL020): HBM may be used for another purpose for which it was 
originally collected, subject to meeting ethical principles/an d is covered by informed consent/ethics approval. In 
the case of secondary use of HBM, (i.e. for new TR projects that are not  specified in the clinical study protocol and 
that were not foreseen at the time of protocol writing) interested parties may apply for the use of HBM and will 
follow the next steps:  
A short description of the new TR projects will be written and submitted to EORTC HQ for coordination with the 
appropriate SSC/Group committee . 
The SSC/Group committee  will prioritize the TR projects. Acc ess procedures defined by the SSC/Group committee  
will build on the following key points:  
♦ Project prioritization  
♦ should be strongly based on scientific merit  
♦ should consider the contribution of the different investigators to the trial and TR project  
♦ will take into consideration if the applicant is an EORTC member or not (whilst maintaining the 
principle of access to the wider scientific community and commitments owed to study participants and 
ethical committees)  
♦ Protection of confidentiality m ust be respected  
♦ An EORTC HQ feasibility check, including recommendations for regulatory and ethical matters and other 
restrictions on the use of the HBM, will take place. If in the event the HBM collections are still retained at 
individual clinical sites,  the TR project leader and the involved EORTC Group are responsible for collecting and 
providing information on availability of HBM for the feasibility assessment  
♦ Prioritized TR projects will then be reviewed by the Translational Research Advisory Committe e (TRAC)  
Once SSC/Group committee  prioritization, the EORTC HQ feasibility assessment, and TRAC review are complete 
and when all applicable competent Ethics Committees approvals are in place and ethical principles are met, the TR 
project can be activated a nd HBM release and analysis can commence.  
The EORTC Executive Committee will mediate any disagreements of opinion between TRAC, the EORTC HQ 
feasibility assessment, the SSC/Group committee  and the TR project leader(s), as needed.  
12 Investigator authorization  procedure  
Investigators will be authorized to register and /or randomize patients in this trial only once they have returned the 
following documents to the EORTC Headquarters:  
♦ The updated signed and dated curriculum vitae of the Principal Investigator  in English with a GCP training 
proof . 
♦ The (updated) list of normal ranges for the investigator’s institution signed and dated by the head of the 
laboratory. Please make sure normal ranges are provided also for those tests required by the protocol but not 
routi nely done at the investigator’s institution.  
♦ The Confirmation of interest by Principal Investigator Form (CIF) , stating that the investigator will fully comply 
with the protocol. This must include an estimate of yearly accrual and a statement on any confli ct of interest 
that may arise due to trial participation.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  73 / 106 September 26, 2016   NB: A signed conflict of interest disclosure form will be required only if a possible conflict is declared on the 
CIF.  
♦ The Study Agreement between EORTC and investigator's institution.  
♦ A copy of t he favorable opinion of the local or national (whichever is applicable) ethics committee mentioning 
the documents that were reviewed (including the version numbers and version dates of all documents). A list 
of all members of the ethics committee is also r equested.  
♦ A copy of the translated and adapted (according to all national requirements) Patient Information / Informed 
Consent sheet. Version numbers and dates must be clearly stated on each page.  
♦ The signature log -list of the staff members with a sample of each authorized signature and the indication of the 
level of delegations. In case patients receive treatment at a satellite institution, i.e. outside the authorized 
institution, details on the satellite institution, including the CV of the local investi gator, normal lab ranges and 
the approval of an ethics committee will have to be transmitted to the EORTC Headquarters. Please keep in 
mind that all communication is done ONLY between the primary institution and the EORTC Headquarters.  
♦ The full name, address, phone numbers and e -mail address of the local pharmacist who will be responsible for 
the trial medication (for any trial where the drug will be provided).  
♦ An accreditation, a certification, an established quality control / external quality assessm ent or another 
validation should be provided for the own laboratory.  
The center specific list of required documents will be included in the protocol activation package, with proper 
instructions as required by this protocol, your group and / or the applicab le national law.  
The new investigator will be added to the “authorization list”, and will be allowed to register/ randomize patients in 
the trial as soon as  
♦ All the above mentioned documents are available at the EORTC Headquarters.  
♦ All applicable national l egal and regulatory requirements are fulfilled.  
Patient randomization from centers not (yet) included on the authorization list will not be accepted.  
13 Patient randomization procedure  
Patient randomization will only be accepted from authorized investigators (see chapter on “investigator  
authorization procedure”).  
Patients should be randomized directly on the EORTC online randomization system  (ORTA = online randomized 
trials access), accessible 24 hours a day, 7 days a week, through the internet.  
To access the interactive randomization program, the investigator needs a username and a password  (which can 
be requested at  http://orta.eortc.be/ ). 
In case of problems investigators can phone the EORTC Headquarters from 9.00 am to 5.00 pm (Belg ian local time) 
from Monday through Friday in order to randomize patients via the EORTC call center.  
Randomization via the phone is not available on Belgian holidays. A list of these holidays is available on  the EORTC 
web site ( http://orta.eo rtc.be/ ) and it is updated annually.  
Through internet:   http://orta.eortc.be/  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  74 / 106 September 26, 2016  In case of problems randomization by phone:  +32 2 774 16 00  
 
A patient can only be randomized after verification of eligibility. Both the eligibility check and randomization 
mus t be done before the start of the protocol treatment.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  75 / 106 September 26, 2016  STANDARD INFORMATION REQUESTED:  
♦ institution number  
♦ protocol number  
♦ step number: 1  
♦ name of the responsible investigator  
♦ patient's code (maximum 4 alphanumerics)  
♦ patient's birth date (day/month/year)  
PROTOCOL SPECIFIC QUESTIONS:  
♦ all eligibility criteria will be checked one by one  
♦ actual values for the eligibility parameters will be requested when applicable  
♦ stratification factors  
♦ date of written informed consent (day/month/year)  
♦ date f oreseen for protocol treatment start  
Once eligibility has been verified, treatment will be randomly allocated to the patient, together with a  sequential 
patient identification number (“seqID”) . This number will allow the identification of the  patients in t he 
VISTA/Remote Data Capture system (VISTA/RDC) that will be used to complete the Case  Report Forms.  
14 Forms and procedures for collecting data  
14.1 Case report forms and schedule for completion  
Data will be reported on the forms  specifically designed by the EORT C Headquarters for this study.  Forms should 
be electronically sent to the EORTC Headquarters through the VISTA/RDC (Remote Data Capture) system with the 
exception of the SAE form which are paper CRFs.  
SERIOUS ADVERSE EVENTS SHOULD BE IMMEDIATELY REPORTED A CCORDING TO THE PROCEDURE DETAILED IN 
THIS PROTOCOL  (see chapter on Reporting Serious Adverse Events) . 
A. Before the treatment starts:  
♦ The patient must be registered/randomized in the trial by INTERNET or in case of problems by phone.  
The electronic CRFs to be completed for a patient are available on the VISTA/RDC website one day after the 
randomization on http://rdc.eortc.be/  or on http://www.eortc. org in the sectio n for investigators.  
B. During/after treatment  
The list of forms to be completed for this study and their submission schedule are available on the VISTA/RDC 
website and are also described in the "guidelines for completion of case report forms" that are pro vided to each 
participating investigator.  
ALL Forms must be  electronically approved  and s ent by the responsible investigator or one of his/her authorized 
staff members  with the exceptio n of the paper SAE form which need to be signed and dated individually  by the 
responsible investigator or one of his/her authorized staff members.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  76 / 106 September 26, 2016  14.2 Data flow  
The forms must be completed electronicall y, with the exception of the SAE form, according to the schedule defined 
in the guidelines  for completion of Case Report Forms.  
The list of staff members authorized to enter data (with a sample of their signature) must be identified on the 
signature log and sent to the EORTC Headquarters by the responsible investigator before the start of the study. To 
enter the RDC system, the inv estigator or authorized staff member needs to use the same username and password 
that are used to access the interactive randomization program (ORTA).  
In all cases, it remains the responsibility of the  principal  investigator to check that data are entered in the database 
as soon as possible and that the  electronic forms  are filled out completely and correctly.  
The EORTC Headquarters  will perform extensive consistency checks  on the received data  and will issue queries in 
case of inconsistent data. The queri es for the electronic forms  will appear in the VISTA/RDC system and must be 
answered  there directly . 
The EORTC data manager will subsequently apply the corrections into the database.  
When satellite institutions are involved , all contact  is made  exclusively with the primary institution, for purposes of 
data collection and all other study related issues.  
If an investigator (or an authorized staff member) needs to modify a CRF after the form has been electronically 
sent  to the EORTC Headquarters , he/she should create a request for data correction in the VISTA/RDC system.  
15 Reporting of Serious Adverse Events  
ICH GCP and the EU Directive 2001/20/EC require that both investigators and sponsors follow specific procedures 
when notifying and reporting adve rse events/reactions in clinical trials. These procedures are described in this 
section of the protocol.  
15.1 Definitions  
These definitions reflect the minimal regulatory obligations; specific protocol requirements might apply in addition . 
AE: An Adverse Event  is defined as “any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product/protocol treatment and which does not necessarily have to have a causal 
relationship with this treatment”. An adverse event  can therefore be any unfavorable and unintended signs (such 
as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including 
results of blood tests, x -rays or scans) or a disease temporarily associated with th e use of the protocol treatment, 
whether or not considered related to the protocol treatment . 
Severity : The term “severe” is often used to describe the intensity (severity) of a specific event  (as in mild, 
moderate or severe, or as described in CTC grades) ; the event itself, however, may be of relative minor medical 
significance (such as severe headache) . This is not the same as “serious,” which is based on patient/event outcome 
or action criteria  usually associated with events that pose a threat to patient ’s life or functioning. Seriousness (not 
severity) serves as a guide for defining regulatory reporting obligations .  
SAE: A Serious Adverse Event  is defined as any untoward medical occurrence or effect in a patient, whether or not 
considered related to the  protocol treatment, that at any dose:  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  77 / 106 September 26, 2016  ♦ results in death  
♦ is life -threatening  (i.e. an event in which the subject was at risk of death at the time of event; it does not refer 
to an event which hypothetically might have caused death if it were more severe)  
♦ requires inpatient's hospitalization or prolongation of existing inpatients´ hospitalization  
♦ results in persistent or significant disability or incapacity  
♦ is a congenital anomaly or birth defect  
♦ results in any other medically important condition (i.e. impo rtant adverse reactions that are not immediately 
life threatening or do not result in death or hospitalization but may jeopardize the patient or may require 
intervention to prevent one of the other outcomes listed above), e.g. secondary malignancy, AE as a  result of 
an overdose  
In this protocol, all complications requiring re -operation/percutaneous radiological drainage have to be 
considered as an SAE . 
Inpatient or in -patient's hospitalization:  A patient who is admitted to a hospital or clinic for at least one overnight  
stay.  
15.2 Exceptions  
The following situations are not considered to be SAEs and should not be reported on the SAE form :  
♦ Elective hospitalization for pre -existing conditions that have not been exacerbated by trial treatment  
♦ A hospitali zation which was planned before the patient consented for study participation and where admission 
did not take longer than anticipated  
♦ Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an 
(S)AE  
♦ Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a 
hospital , palliative care, rehabili tation, overdose without occurrence of an adverse event)  
♦ Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the start of 
the study that do not worsen  
By EORTC convention, clinical events related to the pr imary cancer progression are not to be reported as SAEs, 
even if they meet any of the seriousness criteria from the standard SAE definition, unless the event is more severe 
than expected and therefore the investigator considers that their clinical signific ance deserves reporting.  
15.3 Severity assessment  
The severity of all AE s (serious and non -serious) in this trial should be graded using CTCAE v 4.0 
www.eortc.org \investigators -area \ctc and the Dindo  grade.  
Periods  Pre-operative  Peri-operative  Follow -up 
Guidance for SEVERITY 
assessment  NCI-CTCAE v4 Adapted from Dindo et al.  NCI-CTCAE v4 
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  78 / 106 September 26, 2016  15.4 Causality assessment  
The investigator is obligated to assess the relationship  between protocol treatment and the occurrence of each 
SAE following definitions in this table:  
Relationship to the 
protocol treatment  Description  
Reasonable possibility  There is a reasonable possibility that the protocol treatment caused the 
event  
No reasonable possibility  There is no reasonable possibility that the protocol treatment caused the 
event  
 
The investigator will use clinical judgment to determine the relationship. Alternative causes, such as natural history 
of the underlying diseases, medical history, concurrent conditions,  concomitant therapy, other risk factors, and the 
temporal relationshi p of the event to the protocol treatment  will be considered and investigated.  
The decision will be recorded on the Serious Adverse Event form, if necessary with the reasoning of the principal 
investigator.   
15.5 Expectedness assessment  
The expectedness assessme nt is the responsibility of the sponsor of the study. The expectedness assessment will 
be performed against the following documents: study protocol, PIS/IC. If necessary, the EORTC Clinical Physician 
and/or the EORTC Medical Safety Officer will be consulte d. 
15.6 Reporting procedure for investigators  
This procedure applies to all Serious Adverse Events (SAE s) occurring from the time a subject is  randomized until 60 
days after protocol  surgery and to any SAE that occurs outside of the SAE detection period (after the 60-days 
period), if it is considered to have a reasonable possibility to be  related to the protocol treatment  or study 
participation . 
Randomization  till 60 days after protocol surgery:  All SAEs  
From day 61 after protocol surgery:  Only related SAEs  
 
All reporting must be done by the principle investigator or authorized staff member (i.e. on the signature list)  to 
confirm the accuracy of the report.  
All SAE data must be collected on the study -specific SAE form.  
All SAEs must be reported immediately  and no later than 24 hours  from the time the investigator or staff became 
aware of the event . 
All SAE -related information needs to be provided in English.  
All additional documents in local  language must be accompanied by a translation in English, or the relev ant 
information must be  summarized in  a follow -up SAE report form.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  79 / 106 September 26, 2016  All SAE -related information must be faxed to:  
 EORTC Pharmacovigilance Unit:  
 Fax No. +32 2 772 8027  
To enable the EORTC to comply with regulatory reporting requirements, all initial SAE reports should always 
include the following minimal information: an identifiable patient (SeqID), a suspect medicinal product if 
applicable, an identifiable reporting source, the description of the medical event and seriousness criteria, as well as 
the cau sality assessment by the investigator. Complete  information requested on the SAE form  of any reported 
serious adverse event must be returned within 7 calendar days of the initial report . If the completed form is not 
received within this deadline, the Pharm acovigilance Unit will make a written request to the investigator.  
Queries sent out by the EORTC Pharmacovigilance Unit need to be answered within 7 calendar days.  
All forms need to be dated and signed by the principle investigator or any authorized staff member (i.e. on the 
signature list).  
15.7 Reporting to investigators and competent authorities  
The EORTC Pharmacovigilance Unit will forward all SAE reports within 24 h ours of receipt to the appropriate 
persons within the EORTC Headquarters.  
All unexpected even ts will additionally be forwarded to all participating investigators and Ethics committees . 
The EORTC Pharmacovigilance Unit will take in charge the expedited reporting to the Competent Authorities  
whenever applicable.  
The EORTC Pharmacovigilance Unit will provide a six -monthly summary which will be added in the group meeting 
report and which will be distributed to all participating investigators.  
15.8 Pregnancy reporting  
Pregnancy occurring during a patient’s participation in this trial, although not considered an SAE, must be notified 
to the EORTC Pharmacovigilance Unit within the same timelines as an SAE (within 24 hours) on a Pregnancy 
Notification Form. The outcome of a pregnancy should be followed up carefully and any a bnormal outcome of the 
mother or the child should be reported. This also applies to pregnancies following the administration of the 
investigational product to the father prior to sexual intercourse.  
♦ Any pregnancy in a female subject or in a female partner of a male subject diagnosed during the treatment 
period or within 60 days after protocol surgery must be reported to the EORTC Pharmacovigilance Unit  
♦ This must be reported within 24 hours of first becoming aware of the event by fax, to the Pharmacovigilan ce 
Unit on a Pregnancy Notification Form/Fax  
♦ If a Serious Adverse Event (SAE) occurs in conjunction with the pregnancy, please also complete an SAE form as 
explained in the SAE chapter  
16 Quality assurance  
16.1 Control of data consistency  
Data forms will be enter ed in the EORTC Headquarters database by using the VISTA/ RDC (Remote Data Capture) 
system.  Computerized and manual consistency checks will be performed on newly entered forms; queries will be  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  80 / 106 September 26, 2016  issued in case of inconsistencies. Consistent forms will be vali dated by the Data Manager. Inconsistent  forms will 
be kept "pending" until resolution of the inconsistencies.  
16.2 Audits  
The EORTC Quality Assurance and Control Unit (QA&C) regularly conducts audits of institutions  participating in 
EORTC protocols. These audits are performed to provide assurance that the rights, safety  and wellbeing of subjects 
are properly protected, to assess compliance with the protocol, processes and  agreements, ICH GCP standards and 
applicable regulatory requirements, and to assess th e quality of data.  
The investigator, by accepting to participate in this protocol, agrees that EORTC, any third party (e.g. a  CRO) acting 
on behalf of the EORTC, or any domestic or foreign regulatory agency, may come at any time  to audit or inspect 
their s ite and all subsites, if applicable.  
This audit consists of interviews with the principal investigator and study team, review of documentation  and 
practices, review of facilities, equipment and source data verification.  
The investigator will grant direct a ccess to paper and/or electronic documentation pertaining to the clinical  study 
(e.g. CRFs, source documents such as hospital patient charts and investigator study files) to these  authorized 
individuals. All site facilities related to the study conduct cou ld be visited during an audit (e.g.  pharmacy, 
laboratory, archives …). The investigator agrees to co -operate and provide assistance at  reasonable times and 
places with respect to any auditing activity.  
If applicable, the company(ies) supplying the study dr ug(s) may have access to anonymized data but will not have 
access to source documents.  
If a regulatory authority inspection is announced, the investigator must inform the EORTC Headquarters  QA&C Unit 
immediately (contact at: QualityAssuranceandControlUnit@eortc.be ). 
In this way EORTC can provide support  in preparing and/or facilitating the inspection. EORTC  
representatives/delegates may also attend the inspection.  
16.3 External review of histology  
16.3.1  Forms  
Two electronic "Pathology Review Forms" will be used for this review and will be available on the VISTA/RDC 
website ( http://rdc.eortc.be  or http://www.eortc.be ) 
♦ Local Pathology Form will be completed by the site  
♦ Pathology Review Form will be completed by the reference pathologist   
16.3.2  Shipment of tumor samples  
♦ The local pathologist will send tumor block or 10 unstain ed slides  if block not available and his/her pathology 
report to reference pathologist. Personal data of the patient must be anonymized and replaced by the EORTC 
sequential identification number allocated to this patient at the time of randomization  
♦ Copies of infor med consent cannot be provided  
♦ For procedures and contact details please r efer to Study Procedures Manual  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  81 / 106 September 26, 2016  16.3.3  Reference pathologist  
♦ Will complete the Pathology Review Form  
♦ The blocks (if blocks) will be sent back to the sites  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  82 / 106 September 26, 2016  16.3.3.1  The list of reference pathologists  
♦ List of pathologists for the EORTC investigators is given in the table hereunder  
 The reference pathologist is   the reference pathologist is  
Italy  
Spain  Angelo Paolo Dei Tos  
Chairman of the PSC  
Dept of Pathology  
Ospedale Regionale "Ca' F oncello"  
Via Ospedale, 1  
IT 31100 Treviso  
Italy  
Phone:  +39 0422 322706  
Fax: +39 0422 322663  
E-mail: apdeitos@ulss.tv.it   Germany  
Poland  
Denmark  
Norway  
Sweden  Eva Wardelmann  
Institute of Pathology  
University Hospital Cologne  
Kerpener Str. 62  
D-50937 Cologne  
Phone : +49 221 478 -6363  
Fax: +49 221 478 -6360  
E-mail: eva.wardelmann@uk -koeln.de   
www.uk -koeln.de  
U. K.  C. Fisher  
Consultant Histopathologist  
The Royal Marsden Hospital  
Fulham Road 203  
London SW3 6JJ  
United Kingdom  
Phone:  +44 20 78082631  
Fax: +44 20 78082578  
E-mail: cfisher@icr.ac.uk   The 
Netherlands  
Belgium  
 J.V.M.G. Bovee  
Department of Pathology  
Leiden University Medical Center  
P.O. Box 9600, L1 -Q 
2300 RC Leiden  
The Netherlands  
Phone:  +31 71 5266617  
Fax: +31 71 5266952  
E-mail : j.v.m.g.bovee@lumc.nl  
    
France  
 F. Collin  
Service d’anatomie pathologique  
Center Georges -François -Leclerc  
1, rue du Pr Marion  
21034 - Dijon Cedex  
France  
Phone:  +33 380737500  
Fax: +33 380671915  
E-mail:  fcollin@dijon.fnclcc.fr    
16.4 Other central review procedures  
16.4.1  Quality assurance in radiotherapy  
All documents pertaining to  specific  radiotherapy quality assurance (RTQA ) procedures will be sent to the centers 
after receipt of the signed commitment form at the EORTC Headquarters.  
The QA procedure consists of completing the following, which must be performed prior to site authorization:  
♦ Level I - Facility Questionnaire (FQ) and submission of Beam Output  Audit ( BOA ) 
♦ Level II - Dummy Run without delineation exercise  (DR) 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  83 / 106 September 26, 2016  ♦ Level V - Complex Dosimetry Check (CDC) for all centers usi ng IMRT, including tomotherapy.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  84 / 106 September 26, 2016  During the trial, the following RTQA  procedures must be performed:  
♦ Level III - Limited prospective Individual Case Review (pICR)  
♦ Level IV - Full retrospective Individual Case Review (rICR)  
More information will be found in the separate document " RTQA  Guidelines" which will be sent with the initiation 
package.  
16.4.1.1  Prior to authorization  
16.4.1.1.1  Facility Questionnaire and External Reference Dosimetry Audit  
All EORTC sites seeking  authorization must have  completed the EORTC Facility Questionnaire  (FQ) , which is valid 
for two years . This questionnaire must be completed  electronically and submitted on line.  
The web link is on the web page of the Radiation Oncology Group (ROG) 
http://groups.eortc.be/radio/Qualityassurance.htm  under "ROG Facility Questionnaire ”. 
All centers at authorization must ha ve a valid  (not older than two years)  Beam Output  Audit ( BOA). If a valid BOA 
has not already been submitted, this should be sent electronically (pdf) to the following address:  
qart62092@eor tc.be . 
Further details can be found in the " RTQA Guidelines".  
16.4.1.1.2  Dummy Run without delineation exercise (DR)  
A Dummy Run without delineation exercise (DR) procedure  is mandatory for all centers for their selected irradiation 
technique prior to authorization. In case centers would like to change their treatment technique (possible once 
only during the trial and only from 3D -CRT to IMRT [including tomotherapy]), the DR procedure must be repeated 
with the new technique prior to the change.  
Further details can be found in the " RTQA Guidelines".  
16.4.1.1.3  Complex Dosimetry  Check  
Before the use of IMRT or Tomotherapy on this trial, centers should have successfully completed an IMRT  complex 
dosimetry check (CDC) in accordance with RTQA guidelines. In case centers would like to change their treatment 
technique (possible once only during the trial and only from 3D -CRT to IMRT including tomotherapy), prior to the 
change, the complex dos imetry check procedure must be performed.  
Further details can be found in the " RTQA Guidelines".  
16.4.1.1.4  Patient -specific RTQA program  
For all patients, complete treatment plans must be submitted for central review in DICOM -RT format. The 
Individual Case Review (ICR) encompasses the following:  
♦ All patient digital treatment data must be submitted prior to the start of radiotherapy treatment  
♦ The first three cases per center  will be verified by the study RTQA team before the end of the first week of 
radiotherapy  
♦ Subsequently, 1 out of 10 randomly selected cases will be centrally reviewed  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  85 / 106 September 26, 2016  ♦ In case that the initial or randomly reviewed cases results in minor or major protocol deviations, 
supplementary case reviews may take place  
♦ Beyond the prospective RTQA ICR, retrospe ctive evaluation of every patient's treatment plan will be performed  
All details about the submission procedure and the supplementary forms are described in the "RTQA Guidelines".  
In case of questions or difficulties, please contact the trial RTQA  team at  the following address:  
qart62092@eortc.be . 
17 Ethical considerations  
17.1 Patient protection  
The responsible investigator will ensure that this study is conducted in agreement with either the Declaration of 
Helsinki ( available on the World Medical Association web site ( http://www.wma.net )) and/or the laws and 
regulations of the country, whichever provides the greatest protection of the patient.  
The protocol has been written, and the study will be conducted according to the ICH Harmonized Tripartite 
Guideline on Good Clinical Practice (ICH -GCP, available online 
athttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf ). 
The protocol must be appro ved by the competent ethics committee(s) as required by the applicable national 
legislation.  
17.2 Subject identification  
The name of the patient will neither be asked for nor recorded at the EORTC Headquarters . A sequential 
identification number will be automat ically allocated to each patient registered in the trial. This number will 
identify the patient and will be  included on all case report forms. In order to avoid identification errors, the 
patien t’s code (maximum of 4 alphanumerics)  and date of birth  will a lso be reported on the case report forms.  
17.3 Informed consent  
All patients will be informed about  
♦ the aims of the study  
♦ the possible adverse events  
♦ the procedures and possible hazards to which the patient will be exposed  
♦ the mechanism of treatment allocation  
♦ strict confidentiality of any patient data  
♦ medical records possibly being reviewed for trial purposes by authorized individuals other  than their treating 
physician  
The template of the patient’s informed consent statement is given as a separate document dat ed and version 
controlled to this protocol.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  86 / 106 September 26, 2016  An adapted translation of the PIS/PIC will be provided by EORTC Headquarters and it is the responsibility of the 
Coordinating investigators for this trial (sometimes called National Coordinators) to adapt it to n ational/local 
requirements where necessary . 
The translated informed consent documents are to be submitted to ethics committees for approval. The 
competent ethics committee for each institution must approve the informed consent documents before the center 
can join the study. It is the responsibility of the competent ethics committee to ensure that the translated 
informed documents comply with ICH -GCP guidelines and all applicable national legislation.  
It is emphasized in the patient information sheet that pa rticipation is voluntary and that the patient is free to 
refuse further participation in the protocol whenever he/she wants to. This will not have any impact on the 
patient’s subsequent care. Documented informed consent must be obtained for all patients in cluded in the study 
before they are registered and/or randomized at the EORTC Headquarters . The written informed consent form 
must be signed and personally dated by the patient or by the patient’s legally acceptable representative.  
All of the above must be  done in accordance with the applicable national legislation and local regulatory 
requirements.  
18 Administrative responsibilities  
18.1 The study coordinator  
The Study Coordinator works  closely with the study team to develop the outline and full protocol and di scusses the 
contents of the reports with the study team. The Study coordinator is responsible for publishing the study results. 
He/she will assist the Clinical Research Physician for answering some clinical questions concerning eligibility, 
treatment, and contributes to the medical review of the patients.  
Study coordinator:  
Sylvie Bonvalot  
 
Institut Curie  
26, rue d'Ulm  
75248 Paris CEDEX 05  
France  
Phone : +33 1 56 24 57 69  
E-mail : sylvie.bonvalot@curie.fr  
18.2 The EORTC Headquarters  
The EORTC Headquarters will be responsible for writing the protocol and PIS/IC, reviewing the protocol, setting up 
the trial, collecting case report forms, controlling the quality of the reported data, organizing the medical review 
and generating reports and analyses in cooperation with the Study Coordinator. All methodological questions 
should be addressed to the EORTC Headquarters.  
EORTC HEADQUARTERS  
 Avenue E. Mounierlaan 83/11  
 Brussel 1200 Bruxelles  
 België - Belgique  
 Fax: +32 2 7723545  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  87 / 106 September 26, 2016    
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  88 / 106 September 26, 2016  18.3 The EORTC group  
All questions concerning ongoing membership in the group should be addressed to the chairm an and/or secretary 
of the group.  
For new membership contact Membership Committee at membership@eortc.be  
EORTC Soft Tissue and Bone Sarcoma group  
Chairman:  
Alessandro Gronchi  
Istituto Nazionale dei Tumori  
Menanoma  and Sarcoma Unit, Department of Surgery  
Via Venezian, 1  
IT 20133 Milano  
Italy  
Phone:  +39 02 23903234  
Fax: +39 02 23902404  
E-mail: alessandro.gronchi@istitutotumori.mi.it  
Secretary:   
Bern d Kasper  
UniversitaetsMedizin Mannheim  
Theodor -Kutzer -Ufer 1 - 3 
68167 Mannheim  
Germany  
Phone:  +49 621 3832447  
Fax: +49 621 3831479  
E-mail: bernd.kasper@umm.de   
19 Trial sponsorship and financing  
The Sponsor of the st udy is the EORTC.  
The contact details of the EORTC are:  
 EORTC Headquarters  
 Avenue E. Mounierlaan 83/11  
 Brussel 1200 Bruxelles  
 België - Belgique  
 Phone:  +32 2 7741611  
 Fax: +32 2 7723545  
 e-mail:  eortc@eortc.be  
20 Trial insurance  
A clinical trial insurance has been taken out according to the laws of the countries where the study will be 
conducted. An insurance certificate will be made available to the participating sites at the time of study initiation.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  89 / 106 September 26, 2016  Clinical trial insurance is only valid in centers authorized by the EORTC Headquarters. For details please refer to the 
chapter on investigator authorization.  
21 Publication policy  
All publications must comply with the terms specified in the EORTC Policy 009 “Release of Res ults and Publication 
Policy”  version 4.1 dated 29 November 2011 .  
The final publication of the  main  trial results will be written by the  EORTC  Study Coordinator on the basis of the 
final analysis performed at the EORTC Headquarters and published in a major  scientific journal .  
The final publication of associated translational research studies will be written by the Coordinator of the 
corresponding translational research study.  
Authors of the manuscript (s) will include the Study Coordinator s, the investigators who have included more than 
5% of the eligible patients in the trial (by order of inclusion) , and the statistician and clinical research physician in 
charge of the trial at the EORTC Headquarters . For  publication of translational research results, co -authors will also 
include scientific collaborators who made substantial contribution to the research.  
The title of all manuscripts will include “EORTC”, and all manuscripts will include an appropriate ackn owledgment 
section, mentioning all investigators who have contributed to the trial, the EORTC Headquarters  staff involved in 
the study, as well as supporting bodies (NCI, cancer leagues, supporting company …). 
Prior to submission, a ll publications (papers, abstracts, presentations…) including data pertaining to patients from 
the present trial will be submitted for review to the EORTC Headquarters, to all co -authors , and to the Trial 
Steering Committee . 
The above rules are applicable to  publications involving  any individual patient re gistered/randomized in the trial.   
The EORTC study coordinator will represent EORTC on  the manuscript (s) study. Further authorship positions 
attributed to the EORTC according to the publication policy will b e attributed to  the investigators who have 
included more than 10%  of the eligible patients in the trial (by order of inclusion) . One of the pathologists of the 
pathology review panel will be included in authorship: for studies in which a member of the path ology review 
panel has reviewed > 25% of cases, that pathologist will qualify for authorship, in other cases the pathology review 
panel, in consultation with the board of the STBSG, will decide which pathologist will be author on behalf of the 
pathology re view panel.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  90 / 106 September 26, 2016  Appendix 1: References  
Ref. 1 Porter GA, Baxter NN, Pisters PWT. Retroperitoneal sarcoma. A population -based analysis of 
epidemiology, surgery and radiotherapy. Cancer 2006;106:1610 -6. 
Ref. 2 Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, Laplanche A. Primary retroperitoneal 
sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009;27:31 -
37. 
Ref. 3 Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, et al. Aggressive surgical policies in a 
retrospectively reviewed single -institution cas  series of retroperitoneal soft tissue sarcoma patients. J Clin 
Oncol 2009;27:24 -30. 
Ref. 4 Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft -tissue sarcoma. Analysis of 500 
patients treated and followed at a single in stitution. Ann Surg 1998;228:355 -65. 
Ref. 5 Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological 
analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J S urg Pathol 
1997;21:271 -81. 
Ref. 6 Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F et al. Prognostic factors in 
retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Cent er 
Federation Sarcoma Group. Cancer 2001;92:359 -68. 
Ref. 7 Hassan I, Park SZ, Donohue JH, Nagorney DM, Kay PA, Nasciemento AG et al. Operative management of 
primary retroperitoneal sarcomas: a reappraisal of an institutional experien ce. Ann Surg 2004;239:244 -
50. 
Ref. 8 Stojadinovic A, Leung DHY, Hoos A, Jaques DP, Lewis JJ, Brennan M. Analysis of the prognostic factors 
significance of microscopic margin in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 
2002;235:424 -34. 
Ref. 9 Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft -tissue sarcoma of 
the retroperitoneum. Ann Surg 1990;212:51 -9. 
Ref. 10 Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern 
of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238:358 -70. 
Ref. 11 Bonvalot S, Miceli R, Causeret S, Colombo C, Bouzaiebe H, Le Péchoux C, et al. Aggressive surgery in 
retroperitoneal sarcoma carried out at high -volume centers is safe and associated to an improved local 
control. Ann Surg Oncol 2010; 17:1507 -14. 
Ref. 12 Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M et al. Long -term results of 
intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. 
Int J Radiat Oncol Biol Phys 2001;50:127 -31. 
Ref. 13 Petersen IA, Haddock MG, Donohue JH, Nagorney DM, Grill JP, Sargent DJ et al. Use of intraoperative 
electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat 
Oncol Biol Phys 2002;52:469 -75. 
Ref. 14 Pisters PWT, O’Sullivan B. Retroperitoneal sarcomas: combined -modality treatment approaches. Curr 
Opin Oncol 2002;14:400 -05. 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  91 / 106 September 26, 2016  Ref. 15 Jones JJ, Catton CN, O'Sullivan B, Couture J, Heisler RL, Kandel RA et al. Initial resul ts of a trial of 
preoperative external beam radiation therapy and postoperative brachytherapy for retroperitoneal 
sarcoma Ann Surg Oncol 2002;9:346 -54. 
Ref. 16 Pawlik TM, Pisters PWT, Mikula L, Feig BW, Hunt KK, et al. Long -term resu lts of two prospective trials of 
preoperative external beam radiotherapy for localized intermediate - or high -grade retroperitoneal soft 
tissue sarcoma. Ann Surg Oncol 2006;13:508 -17 
Ref. 17 Catton C, O’Sullivan B, Kotwall C, Cummings  B, Hao Y, Fornasier V. Outcome and prognosis in 
retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29:1005 -10. 
Ref. 18 Van Doorn RC, Gallee MP, Hart AA, et al. Resectable retroperitoneal soft tissue sarcoma: The effect of the 
extent of resection and postoperative radiation therapy on local tumor control. Cancer 1994;73:637 -
42.Heslin MJ, Lewis JJ, Newman E, et al. Prognostic factors with long -term survival for retroperitoneal 
sarcoma: implications for mangement. J Clin Oncol 1997;15:2832 -39. 
Ref. 19 Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, et al. Intraoperative 
radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. A rch 
Surg 1993;128:402 -12 
Ref. 20 Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbette P, Patel M, Ghert M. A systematic review and 
meta -analysis of oncologic outcomes of pre - versus postoperative radiation in localized resectable so ft-
tissue sarcoma. Ann Surg Oncol 2010;17:1367 -74. 
Ref. 21 Pisters PWT, Ballo MT, Fenstermacher  MJ, et al. Phase I trial of preoperative doxorubicin and radiation 
therapy, surgocal resection, and intraoperative electon -beam radiation therapy for patients with localized 
retroperitoneal sarcoma . J Clin Oncol 2003;21:3092 -97. 
Ref. 22 ICRU Report 50. Prescribing, Recording and Reporting Photon Beam Therapy. International Commission 
on Radiation Units and Measurements (1993).7910 Woodmont Avenue, Bethesda, MD 20814, USA.  
Ref. 23 ICRU Report 62. Prescribing, Re cording and Reporting Photon Beam Therapy (Supplement to ICRU Report 
50). International Commission on Radiation Units and Measurements (1999).7910 Woodmont Avenue, 
Bethesda, MD 20814, USA.  
Ref. 24 ICRU Report 83. Prescribing, Recordi ng and Reporting Photon -Beam Intensity -Modulated Radiation 
Therapy (IMRT) (2010). 7910 Woodmont Avenue, Bethesda, MD, 20814, USA.  
Ref. 25 Sanguineti G, Little M, Endres E, Sormani M, Parker B. Comparison of three strategies to deline ate the 
bowel for whole pelvis IMRT of prostate cancer. . Radiother Oncol 2008;88(1):95 -101.  
Ref. 26 E. Eisenhauer, P. Therasse, J. Bogaerts et al. New Response Evaluation Criteria in Solid Tumors: Revised 
RECIST Guideline (Version1.1). Eur J Cancer. 2009 Jan;45(2):228 -47 
Ref. 27 Dindo D, Demartines N, Clavien PA. Classification of surgical complications. A new proposal with 
evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205 -213.  
Ref. 28 Hwang IK, Shih WJ, DeCani JS. Group sequential designs using a family of type I error probability spending 
functions. Stat Med 1990; 9:  1439 –45 
Ref. 29 Kaplan EL, Meier P. Nonparametric estimation from incomplet e observations. J Am Stat Assoc 1958; 
53:457 -481.  
Ref. 30 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Second edition, John  Wiley, 2002.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  92 / 106 September 26, 2016  Ref. 31 Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:  187-220.  
Ref. 32 Lin, D., Wei, L., and Ying, Z. Checking the Cox Model with Cumulative Sums of Martingale -Based 
Residuals," Biometrika, 1993;80, 557 - 572.  
Ref. 33 Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK 4 amplification in well -
differentitated and dedifferentiated liposarcomas. Clin Cancer Res 2009;15:5696 -703 
Ref. 34 Coindre JM, Holstein I, Marie G, et al. Inflammatory malignant fibrous histiocytofibroams and 
dedifferentiated liposa rcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a 
single entity. J Pathol 2004;203:822 -30. 
Ref. 35 Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well -differentiated and 
dedif ferentiated liposarcomas whereas CDK4 belongs to distinct inconsistent amplicon. Int J Cancer 
2008;122:2233 -41 
Ref. 36 Shimida S, Ishizawa T, Ishizawa K, et al. The value of MDM2 and CDK4 amplification levels using real -time 
polymera se chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. 
Hum Pathol 2006;37:1123 -9 
Ref. 37 Erickson -Johnson MR, Seys AR, Roth CW, et al. Carboxypeptidase M: a biomarker for the discrimination o f 
well-differentiated liposarcoma from lipoma. Mol Pathol 2009;22:1541 -7 
Ref. 38 Snyder EL, Sandstrom DJ, Law K, et al. C -Jun amplification and overexpression are oncogenic in 
liposarcoma but not always sufficient to inhibit adipocyt ic differentiation programme. J Pathol 
2009;218:292 -300.  
Ref. 39 Marks LB, Yorke ED, Jackson A et al. Use of normal tissue  complication probability models in the clinic. 
Int. J. Rad. Onc. Biol. Phys.  2010; 76: S10 -S19.  
Ref. 40 Aaronson -NK; Ahmedzai -S; Bergman -B; Bullinger -M; Cull -A; Duez -NJ; Filiberti -A; Flechtner -H; Fleishman -
SB; et al. The European Org anization for Research and Treatment of Cancer QLQ -C30: a quality -of-life 
instrument for use in international clinical trials in oncology. J -Natl-Cancer -Inst. 1993 Mar 3; 85(5): 365 -76 
Ref. 41 Blazeby JM, Conroy T, Bottomley A, et al . Clinical and Psychometric Validation of a Questionnaire Module, 
the EORTC QLQ -STO22, to Assess Quality of Life in Patients with Gastric Cancer. Eur J Cancer 40:2260 -
2268, 2004.  
Ref. 42 Whistance RN, Conroy T, Chie W, et al. Clinica l and Psychometric Validation of the EORTC QLQ -CR29 
Questionnaire Module to Assess Health -Related Quality of Life in Patients with Colorectal Cancer. Eur J 
Cancer 45:3017 -3026, 2009.  
Ref. 43 Osoba D, Rodrigues G, Myles J, Zee B, Pate r J. Interpreting the significance of changes in health -related 
quality -of-life scores. J Clin Oncol 1998; 16: 139 -44. 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  93 / 106 September 26, 2016  Appendix 2: Abbreviations  
 
3D-CRT 3 D conformal Radiotherapy  
AE   Adverse Event  
ALT  Alanine aminotransferase  
ASA  American Society of Anesthesiologist  
ASC  Anesthesia and Surgical Care  
ASK 1   Apoptosis signal -regulating kinase  1 
AST  Aspartate aminotransferase  
HBM   Human Biological Material (HBM)  
CNS  Central nervous system  
CDC  Complex Dosimetry e -check  
CR   Complete Response  
CRF  Case Report form  
CRO   Clinical Research Organization  
CT   Computed Tomography  
CTC  Common Toxicity Criteria  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP   Cancer Therapy Evaluation Program  
CTV  Clinical Target Volume  
CV   Curriculum Vitae  
DICOM  Digital Imaging Communication in Medicine  
DR   Dummy Run  
DSMB   Data and Safty Monitoring Board  
EB-IORT  Electron -beam intraoperative radiation  
EBRT   External -beam radiotherapy  
EBIORT  Electron beam i ntraoperativ e radiation t herapy  
ERDA   External Reference Dosimetry Audit  
FDG   Fluorodeoxy -D-glucose  
FFP  Fresh Frozen Plasma  
FQ   Facility Questionnaire  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  94 / 106 September 26, 2016  GFR  Glomerular filtration rate  
GIST   Gastro -intestinal stromal tumor  
GTV  Gross Tumor Volume  
H0   Null Hypothesi s 
HMGCOA  3-hydroxy -3-methylglutaryl -coenzyme A  
HR   Hazard Ratio  
IC   Intermediate Care  
ICH/GCP  International Conference on Harmonisation /Good Clinical Practice  
ICR  Intra Cavitory Radiation  
ICRU   International Commission on Radiation Units and measurements  
ICU  Intensive Care unit  
IDMC   Independent Data Monitoring Committee  
IMRT   Intensity -modulated radiotherapy  
IORT   Intra -operative radiotherapy  
ITT  Intent to treat  
IVC  Internal vena cava  
MRI  Magnetic Resonance Imaging  
MV  Mega Volt  
NCI  US N ational Cancer Institute  
NYHA   New York Heart Association  
OAR   Organs at Risk  
ORTA   Online randomi zed trials access  
OTT   Overall Treatment Time  
PCR  Polymerase chain reaction  
PD   Progression  
PET   Positron Emission Tomography  
PIS/IC   Patient Informatio n Sheet/ Inform Consent  
PLT  Platelet  
PNET   Primitive Neuroectodermal Tumor  
PR   Partial Response  
PTV  Planning Target Volume  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  95 / 106 September 26, 2016  QA   Quality Assurance  
RBC  Red Blood Cell  
RDC  Remote Data Capture  
RECIST  Response Evaluation Criteria In Solid Tumors  
RPS  Retroperitoneal sarcoma  
RT   Radiation Therapy  
RTQA   Radiotherapy quality assurance  
SAE  Serious adverse Event  
SAL  Shrinking Action level  
SD   Stable Disease  
seqID   sequential patient identification number  
SOC  System Organ Class  
SOP  Standard Operation P rocedure  
STBSG  Soft Tissue and Bone Sarcoma Group  
TR   Translational research  
ULN   upper limit of normal  
VISTA   Visual Information System for Trial Analysis  
WHO   World Health Organization  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  96 / 106 September 26, 2016  Appendix 3: WHO performance status s cale 
Grade  Performance scale  
0 Able to carry out all normal activity without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out light 
work . 
2 Ambulatory and capable of all self -care but unable to carry out any work; up and 
about more than 50% of waking hours.  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled; cannot carry on any self -care; totally confined to bed or chair.  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  97 / 106 September 26, 2016  Appendix 4: New York Heart Association (NYHA) 
classification of heart failure  
 
Class I  Patients with cardiac disease but without resulting limitations of physical activity. Ordinary 
physical activity does not cause undue fatigue, palpitation, dyspnoea or anginal pain.  
Class II  Patients with cardiac disease resulting in slight limitation of phy sical activity. They are comfortable 
at rest. Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain.  
Class III  Patients with cardiac disease resulting in marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnoea or 
anginal pain.  
Class IV  Patients with cardiac disease resulting in inability to carry on physical activity without discomfort. 
Symptoms of cardiac insufficiency or of the anginal  syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort is increased.  
 
(The Criteria Committee of the New York Heart Association: Diseases of the Heart and Blood Vessels; 
Nomenclature and Criteria for Diagnosis, 6th ed Bo ston, Little, Brown 1964).  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  98 / 106 September 26, 2016  Appendix 5: Calculation of the glomerular filtration 
rate (GFR)  
 
COCKCROFT AND GAULT FORMULA  
 
For the calculation of GFR age is measured in years and weight is measured in kilograms.  
 
 
 
If serum creatinine is measured in µmol/l, the following formula applies:  
 
In males :     GFR[ml/min]   =  1.23 x (140 - age) x weight  
      serum creatinine  
 
In females :  GFR[ml/min]   = 1.05 x (140 - age) x weight  
      serum creatinine  
 
 
If serum creatinine is measured in mg/dl, the following formula applies:  
 
In males :     GFR[ml/min]   =  (140 - age) x weight  
       72 x serum creatinine  
 
In females :  GFR[ml/min]   = 0.85 x (140 - age) x weight  
      72 x serum creatinine  
 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  99 / 106 September 26, 2016  Appendix 6: Common Terminology Criteria for 
Adverse Events  
In the present study, adverse events and/or adverse drug reactions will be recorded according to the  
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 
At the time thi s protocol was issued, the full CTC document was available on the NCI web site, at the following 
address:     http://ctep.cancer.gov/reporting/ctc.html . 
The EORTC Headquarters web site   www.eortc.org \investigators -area \ctc   provides a link to the appropriate CTC 
web site. This link will be updated if the CTC address is changed.  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  100 / 106 September 26, 2016  Appendix 7: EORTC Quality of Life evaluation: 
guidelines for administration of checklists  
 
           
EORTC Quality of Life evaluation: guidelines for administration of checklists  
The instructions given below are intended to provide  some general guidelines for collecting quality of life (QOL) 
data in EORTC studies.  
1. Who is the responsible person (RP) for QOL data collection?  
In each institution, the principal investigator  is the responsible for the local organization of QoL data collection. 
This can be delegated to a physician, data manager, (research) nurse or a psychologist. Such a person should have 
the full protocol at his/her disposal as well as the questionnaire(s). This person would also be the intermediate 
contact point in case of any necessary clarification asked by the EORTC Headquarters.  
2. Who should fill out the checklist?  
In principle it is the patient  who has to complete the QOL forms and preferably without h elp from others. In the 
case where a patient is too sick to fill out the checklist by him/herself or if the patient is not able to complete the 
checklist for such reasons as forgetting his/her glasses, another person could read the questions without making  
any suggestions and report the answers on the forms. It is not allowed for another person to fill in the checklist as 
if (s)he was the patient (proxy assessment) unless specifically allowed by the protocol.  
3. What instructions should be given to the pati ent?  
At entry in a study , the RP should give the patient an explanation of the objective of the study and instructions for 
completing the checklist.  
The patient should be informed that participation in the QOL protocol is voluntary and that the information  
provided is confidential (identification is only for administrative purposes and includes date of birth and today’s 
date (completion date)).  
The following issues should be explained to the patient:  
♦ The schedule of assessments.  
♦ The checklist is a self admi nistered checklist that should be completed by the patient him(her)self. The patient 
can ask for aid in reading or writing but should not let another person provide the answers.  
♦ The patient should   circle   the choice that best corresponds to his/her sit uation.  
♦ There is no right or wrong answer to any of these questions. The answers will not influence any  medical 
decision making.  
♦ All questions should be answered.  
♦ The patient will be given a checklist in the default language(s) of the hospital. If desire d, the  patient may 
request another language. The RP will then contact the EORTC Headquarters for the  appropriate translation.  

EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  101 / 106 September 26, 2016  The RP should make sure that the patient understands the instructions.  
At each subsequent assessment as defined by the protocol,  the patient should receive the checklist from the RP or 
from other appropriate staff if the RP is unavailable.  
4. Where should the patient complete the checklist?  
The patient should complete the checklist at the clinic, and, ideally in a quiet, private ro om. If this is not possible, 
the waiting room is an acceptable alternative. In general it does not take long to complete the checklist, but 
patients should be given the time they need to answer all questions.  
5. When should they complete the checklist?  
The timing of the planned QoL assessments is detailed in the protocol. When a QOL assessment is planned, the 
checklist should be given to the patient preferably before the meeting with the physician, ensuring that the patient 
has enough time to complete the c hecklist. If the patient is to receive a therapy, the checklist should be filled out 
before administration of the treatment (unless indicated otherwise in the protocol). The checklist should not  be 
taken home and/or mailed (unless indicated otherwise in th e protocol).  
6. Review of the completed checklist  
After the patient has completed the checklist, the person handling the checklist should:  
♦ Complete the “Hospital Staff” specific data box.  
♦ Check that the completion date is correctly filled in by the patient.  
♦ Screen the checklist for omissions.  
If this is the case:  
♦ Please ask the patient the reason for omissions. It may be that patient forgot to flip a page or did not 
understand a question. The patient should not be forced to provide an answer if (s)he  does not wish to do so.  
♦ Additional explanation may be provided, but the questions should not be rephrased.  
7. Missing forms  
If for some reason the patient is unable or does not wish to complete a quality of life checklist the reason and the 
date of visit should be documented on the corresponding CRF (case report form).  
8. Mailing to EORTC Headquarters  
A copy of the checklists should be sent to EORTC Headquarters as soon as possible, while the original source 
document should be kept on site. As it is impos sible to retrospectively collect missing quality of life data, please 
make sure the patient completes the checklist at the time -point when he/she is supposed to complete it.  
Thank you very much for your cooperation. If you have any remarks about this leafl et or if you need further 
information, please contact:  
Quality of Life Department - EORTC Headquarters:  
Phone: 32 2 774 16 61/16 06  
Fax: 32 2 772 35 45  
E-mail: qualityoflife@eortc.be  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  102 / 106 September 26, 2016  Appendix 8: American Society of Anesthe siologists 
score  
The ASA Score is a system for assessing the risk for postoperative morbidity/mortality. In 1963 the American 
Society of Anesthesiologists  (ASA) adopted the five -category physical status classification system; a sixth category 
was later added:  
 
Score   
1 A normal healthy patient . 
2 A patient with mild systemic disease . 
3 A patient with severe systemic disease . 
4 A patient with severe systemic disease that is a constant threat to life 
5 A moribund  patient who is not expected to survive without the operation  
6 A declared brain -dead  patient whose organs  are being removed for donor  purposes  
 
Reference : 
Owens WD, Felts JA, Spitznagel  EL (1978). "ASA physical status classification: A study of consistency of ratings". 
Anaesthesia 49: 239 –43 
Link: http://www.ncbi.nlm.nih.gov/pubmed/697077  
  
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  103 / 106 September 26, 2016  Appendix 9: EORTC QlQ -C30 (version 3)  
 
 
EORTC QLQ -C30 (version 3)  
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling 
the number that best applies to you. There are no "right" or "wrong" answers. The informati on that you provide 
will remain strictly confidential.  
Your birthdate (Day, Month, Year):    
Today's date (Day, Month, Year):  23  
___________________________________________________________ __________________________  
           Not at  A Quite
 Very  
           All Little  a Bit
 Much  
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase?    1 2 3 4 
2. Do you have any trouble taking a long walk?     1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house?  1 2 3 4 
4. Do you need to stay in bed or a chair during the day?    1 2 3 4  
5. Do you need help with eating, dressing,  washing  
 yourself or using the toilet?       1 2 3 4 
 
During the past week:        Not at  A Quite  Very  
           All Little  a Bit
 Much  
6. Were you limited in doing either your work or other daily activities?  1 2 3 4 
7. Were you limited in pursuing your h obbies or other  
 leisure time activities?        1 2 3 4 
8. Have you had pain?        1 2 3 4 
9. Did you need to rest?        1 2 3 4 
10. Have you felt weak?        1 2 3 4 
FOR THE PATIENT  
TO BE COMPLETED BY HOSPITAL STAFF (EN)  
Protocol: 62092   Form 930, page 1 of 2   
Date completed by patient  (DD/MM/YY) └─┴─ ┘ / └ ─┴─ ┘ / └ ─┴─┴─┴─┘ 
Inst  └─┴─┴─┴─┘   Seq id  └─┴─┴─┴─ ┘           Patient Code  └─┴─┴─┴─ ┘         
 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  104 / 106 September 26, 2016  11. Have you lacked appetite?       1 2 3 4 
12. Were you tired?         1 2 3 4 
13. Did p ain interfere with your daily activities?     1 2 3 4 
14. Has your physical condition or medical treatment  
 interfered with your family life?       1 2 3 4 
15. Has your physical condition or medical treatment  
 interfered with your social activities?      1 2 3 4 
Please go on to the next page   
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  105 / 106 September 26, 2016   
 
 
 
 
 
For the following questions please circle the number between 1 and 7 that best applies to you  
 
16. How would you rate your overall health during the past week?  
  1 2 3 4 5 6 7 
 Very poor       Excellent  
 
17. How would you rate your o verall quality of life during the past week?  
  1 2 3 4 5 6 7 
 Very poor       Excellent  
 
During the past week:       Not at  A Quite  Very  
          All Little  a Bit  Much  
18. Have you had discomfort when eating?     1 2 3 4 
19. Have you had pain in your stomach area?    1 2 3 4 
20. Have you had discomfort in your stomach area?    1 2 3 4 
 
During the past 4 weeks :      Not at  A Quite  Very  
          All Little  a Bit  Much  
For men only:  
21. To what extent were you interested in sex?    1 2 3 4 
22. Did you have difficulty getting or maintaining an erection?  1 2 3 4 
 
For women only:  
21. To what extent were you interested in sex?    1 2 3 4 
22. Did you have pain or discomfort during intercourse?   1 2 3 4 FOR THE PATIENT  
TO BE COMPLETED BY HOSPITAL STAFF (EN)     
Protocol°: 62092   Form 930, page 2 of 2   
Date completed by patient  (DD/MM/YY) └─┴─ ┘ / └ ─┴─ ┘ / └ ─┴─┴─┴─┘ 
Inst  └─┴─┴─┴─┘   Seq id  └─┴─┴─┴─ ┘           Patient Code  └─┴─┴─┴─ ┘         
 
EORTC 62092 -22092  Study of pre -operative XRT in RPS/ STRASS  
Version 3.1  106 / 106 September 26, 2016   
 
© Copyright 2013 EORTC Quality of Life Group. All rig hts reserved.  